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CHAPTER I 
INTRODUCTION 
The objective of this dissertation was to investigate the location of 
serotonergic receptors mediating renin release. Serotonin agonists have 
been shown to increase plasma renin activity (PRA) and plasma renin 
concentration (PRC) when injected peripherally (Van de Kar, 1991). The 
pathway and location of the receptors involved in this endocrine control 
remain unclear. 
The overall function of the kidney is to maintain body fluid 
homeostasis. This encompasses maintaining blood pressure, blood volume 
and electrolyte balance. In this way, the kidney is the ultimate 
controller of the body's blood pressure set-point (Guyton et al., 1972). 
The renin-angiotensin system is a vital component of the kidney's 
regulatory mechanisms. The active product of this cascade is the peptide 
angiotensin II. Angiotensin II is a potent vasoconstrictor, stimulates 
aldosterone release from the adrenal gland, and activates receptors in the 
brain to induce thirst. The control of renin secretion from the kidney is 
a complex array of interconnected mechanisms including: renal stretch 
receptors which sense blood pressure changes, the macula densa which 
senses sodium changes, the sympathetic nervous system, and many hormones 
(Hackenthal et al., 1990). The primary regulatory hormone is angiotensin 
1 
2 
II, which feeds back to the kidney to inhibit renin release (Vallotton, 
1987). 
Serotonin (5-HT) is found predominately in three locations, the gut, 
circulating platelets, and the brain (Grahame-Smith, 1988). Established 
as a neurotransmitter since the mid 1950's, 5-HT is now known to influence 
the secretion of many hormones including: ACTH and corticosterone (Fuller, 
1990), oxytocin (Saydoff et al., 1991), prolactin (Van de Kar and Bethea, 
1982) and vasopressin (Brownfield et al_, 1988). That renin may also be 
regulated by 5-HT was determined in the early 1980 's (Zimmerman and 
Ganong, 1980; Van de Kar et al., 1981). 
Serotonin pharmacology has seen an outburst of drug development since 
Peroutka and Snyder (1979) described multiple families of 5-HT receptors 
in the brain. Currently, conclusive evidence exists for 5-HTlA, 5-HTiB/lD, 
5-HT1c, 5-HT2 and 5-HT3 receptor subtypes (Frazer et al., 1990). Several 
studies suggest that renin is regulated through 5-HT2 receptors (Alper, 
1990a; Van de Kar et al., 1989; Bagdy et al., 1992). In attempting to 
answer the questions posed by this dissertation, many pharmacological 
"tools" were utilized. The important serotonergic drugs employed were the 
5-HT1AJ'5-HT1B agonist RU 24969, the 5-HT1c/5-HT2 agonist DOI, and the 5-HT 
releaser p-chloroamphetamine (PCA). A listing of all the drugs used in 
these studies can be found on page xi. 
A debate exists concerning two issues. One, whether 5-HT agonists act 
at peripheral (Alper and Snider, 1987) or central sites (Karteszi et al., 
1982; Van de Kar et al., 1982) to stimulate renin release. Two, if 
centrally controlled, whether the 5-HT receptors are located in either the 
paraventricular (PVN) or ventromedial nucleus (VMN) of the hypothalamus 
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(Gotoh et al., 1987; 1988). The specific aims of this dissertation 
attempted to resolve these two questions. 
First, to establish if the renin releasing effect of 5-HT agonists has 
a central site of action, the 5-HT agonists DOI, RU 24969 and the 5-HT 
releaser PCA were injected through cannulae into the lateral cerebral 
ventricles of conscious rats. A dose-response experiment was performed 
with each drug. The receptor mediating renin release appears to be of the 
5-HT2 subtype. Therefore, to test whether a 5-HT2 antagonist could block 
the effect of the 5-HT agonist, a 5-HT2 antagonist was pre-injected through 
the same cannulae. 
An experiment to determine if peripheral receptors contribute to the 
renin releasing effects of 5-HT agonists was also performed. 
antagonist was injected through cannulae into the lateral ventricles of 
the brain, followed by peripheral administration of a 5-HT agonist. In 
addition, the effects of each 5-HT agonist on blood pressure and heart 
rate were determined in separate control experiments. 
Second, once a central site was established, experiments were 
conducted to determine where in the hypothalamus 5-HT receptors were 
located that mediate the release of renin. Chemical lesions were made by 
injecting the neurotoxin ibotenic acid into the PVN or VMN. Ibotenic acid 
lesions were also made in the dorsomedial nucleus which served as a 
hypothalamic control site. Ibotenic acid destroys cell bodies while 
sparing axons which pass through the injection site. PRA and PRC were 
measured following intraperitoneal (ip) administration of RU 24969 or PCA. 
The ramifications of these studies could influence how we view renin 
regulation, and the important contribution the brain has in this process. 
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Furthermore, these studies could lead to development of anti-hypertensive 
agents designed for specific sites and receptor targets. 
The hypothesis of this dissertation is that cell bodies in the 
hypothalamic paraventricular nucleus contain 5-HT receptors that stimulate 
renin secretin. The results obtained from these studies suggest that 
neurons located in the PVN are indeed necessary to mediate renin release 
induced by a 5-HT agonist, and a 5-HT releaser. The receptors involved in 
this function are likely serotonergic. The mechanism whereby the PVN 
communicates with the kidney remains unresolved. 
The body of the dissertation is organized as three papers, either 
published (chapter 3) or submitted for publication (chapters 4 and 5). 
The text of these chapters has remained unaltered from the form they were 
in when submitted for publication. 
chapters. 
A general discussion follows these 
CHAPTER II 
REVIEW OF RELATED LITERATURE 
This dissertation was designed to investigate the influence of brain 
serotonergic neurons on the renin-angiotensin-system. The long-term goal 
of this project is to provide additional information on the role of 5-HT 
and renin in the etiology of hypertension. Background information is 
divided into two sections: literature related to the renin-angiotensin 
system, and literature related to serotonin_ 
The Renin-Angiotensin System 
The Renin-Angiocensin-Aldoscerone Syscem 
History. The discovery of renin occurred in 1897 when Tigerstedt and 
Bergman injected renal extracts into rabbits and produced a pressor 
response. This idea was not extended until 193~ when Goldblatt generated 
"renal" hypertension by occluding the renal arteries, thus demonstrating 
the connection between renin and high blood pressure (Keeton and Campbell, 
1980). By 1940, Page recognized that renin was an enzyme which produced 
an even more potent pressor substance, termed "angiotonin". Nearly 
simultaneously, Braun-Menendez discovered the peptide "hypertensin" 
generated from renin incubated with plasma. The name angiotens in was 
5 
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agreed upon in 1957 by consensus (Keeton and Campbell, 1980). Tobian 
(1959) developed the hypothesis of a renal "stretch", or baroreceptor, 
that was sensitive to changes in blood pressure and blood volume. Thus 
began the pursuit of how sodium and blood volume were related to the 
development of hypertension. The macula densa hypothesis that changes in 
electrolytes could be "sensed" by the kidney was advanced by Vander 
(1965). 
The renin-angiotensin system (RAS) is a unique enzymatic-hormonal 
cascade that can be stimulated by hypotension (10 to 20 mm Hg below 
normal), fluid loss caused by hemorrhage, diarrhea or vomiting, and low 
sodium diet. Thus, there appear to be four major mechanisms controlling 
renin secretion: 1. hemodynamic or renal perfusion pressure, mediated by 
stretch receptors, 2. neurogenic, mediated by sympathetic adrenergic (p 
and/or a) receptors, 3. sodium load, mediated by the macula densa, and 4. 
hormonal, mediated by a multitude of substances including ANG II, 
prostaglandins, adenosine, vasopressin, atrial natriuretic peptide and 
other peptides and ions. Renin is thus highly regulated by numerous 
integrated factors discussed more fully below (Vallotton, 1987; Dzau and 
Pratt, 1986; Keeton and Campbell, 1980). 
Renin is the rate limiting enzyme in the sequence producing the active 
octapeptide angiotensin II (ANG II). Renin is a 40,000 dalton aspartyl 
protease secreted by the juxtaglomerular cells located along the afferent 
arterioles of the kidney. Renin has high substrate specificity, with only 
one known substrate (Hackenthal et al., 1990). 
Renin substrate, angiotensinogen (60-65 kDa), is secreted in 
relatively constant amounts by the liver. Angiotensinogen concentration 
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in plasma is normally below the Km of the renin-angiotensinogen reaction 
(Dzau and Pratt, 1986). ANG II feeds back to increase the synthesis of 
angiotensinogen mRNA (Nakamura et al., 1990). Some evidence exists 
suggesting that the hypothalamus may be involved in angiotensinogen 
regulation (Kjos et al., 1991). A ten amino acid peptide with little 
intrinsic activity of its own, angiotensin I, is cleaved by renin from 
this substrate. The production of angiotensin I is measured in plasma 
renin activity (PRA) and plasma renin concentration (PRC) assays. 
The ubiquitous endothelium-bound converting enzyme then transforms 
angiotensin I to ANG II, by cleaving off an additional two amino acids. 
Converting enzyme, a peptidyl dipeptidase, is found throughout the 
vasculature, including the kidney and liver, with highest concentrations 
lining capillary endothelium of the lungs (Vallotton, 1987). Unlike 
renin, converting enzyme lacks substrate specificity. Converting enzyme 
plays a dual role as kininase II, which is the enzyme responsible for the 
inactivation of bradykinin, a potent vasodilator (Vallotton, 1987). 
Because renin and its substrate are blood borne, the formation of ANG 
II can occur anywhere along the vasculature where converting enzyme is 
located. Also, since ANG II is blood borne, its targets are widely 
located. ANG II receptors have been identified in targets reflecting its 
diverse actions: the adrenal (zona glomerulosa), vascular smooth muscle, 
uterus, bladder, glomeruli, platelets, pituitary, and brain (Dzau and 
Pratt, 1986). Two ANG II receptor subtypes have recently been 
characterized, defined as AT1 and AT2 (Whitebread et al., 1989; Chiu et 
al., 1989). AT1 receptors are coupled to G regulatory proteins, stimulate 
phosphoinositol turnover, and have been localized in the brain (Tsutsumi 
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and Saavedra, 1991). AT2 receptors have not been thoroughly characterized. 
Binding to ANG II receptors is stereoselective and saturable (Dzau and 
Pratt, 1986). 
The subsequent actions of ANG II include stimulation of the secretion 
of the Na+ -conserving mineralocorticoid hormone aldosterone from the 
adrenal cortex. Aldosterone acts at the distal tubule as the primary 
sodium conserving hormone in the body. ANG Il is the principal regulator 
of aldosterone secretion. ANG II stimulates presser pathways located in 
the brain (Hartle and Brody, 1984). Receptors for blood borne ANG II have 
been identified with autoradiography in the subfornical organ, median 
eminence, organurn vasculosum of the lamina terminalis (OVLT) and the area 
postrema (van Houten et al., 1980). These sites are circumventricular 
organs which lie outside the blood-brain barrier. Immunohistochemistry 
has stained for ANG II cell bodies in the magnocellular neurons of the 
hypothalamic PVN, as well as for fibers in the brainstem and limbic sites 
(Lind et al., 1985). ANG II also stimulates thirst through CNS receptors 
located in the subfornical organ. The drinking behavior induced by ANG II 
is prevented by the ANG II antagonist saralasin (Mangiapane and Simpson, 
1980). Finally, ANG II is a powerful vasoconstrictor of arteriolar smooth 
muscle. Thus, these combined actions are vital for the maintenance of 
blood volume and fluid homeostasis. 
The importance of the RAS in maintaining blood pressure is evidenced 
by the ability of both P-blockers such as propranolol, which inhibit renin 
secretion, and converting enzyme inhibitors such as captopril to 
effectively lower BP in hypertensive patients (Dzau and Pratt, 1986; 
Keeton and Campbell, 1980; Vallotton, 1992). The role of the RAS in 
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hypertension is discussed more fully below. The RAS does not appear to 
play as prominent a role in maintenance of normal blood pressure as does 
the sympathetic nervous system. Ganglionic blockade lowers normal 
pressure to a greater extent than RAS blockade. Thus, the sympathetic 
nervous system plays the primary role, while the RAS acts in more of a 
support capacity, becoming fully activated at pressures of approximately 
80 to 90 mm Hg (Zimmerman et al., 1984). Some evidence suggests that 
during normal fluctuations in BP, the RAS may contribute substantially to 
normalizing the pressure, for example as occurs during orthostatic 
hypotension (Hackenthal et al., 1990). 
A recent area of research has focused on localized tissue renin-
angiotensin systems (Dzau and Pratt, 1986). The postulated locations 
include blood vessels, brain, adrenal, testis, heart and kidney. The 
actions of ANG II in the brain, as outlined above include stimulation of 
the sympathetic nervous system and blood pressure, increased release of 
vasopressin and ACTH, inducement of drinking behavior and elevated Na+ 
appetite. While these responses can be elicited by either iv or 
intracerebroventricular (ICV) administered ANG II, the variety of 
responses suggests the presence of a local synthetic pathway (Reid, 1984; 
Mendelsohn et al., 1990). Initial evidence for a brain RAS developed when 
binding sites for ANG II (Castren and Saavedra, 1988) and cells containing 
ANG II (Healy and Printz, 1984) were observed in the PVN, clearly a 
structure within the blood brain barrier. However, whole brain 
angiotensinogen mRNA levels are substantially higher than renin mRNA 
levels (Dzau et al., 1986). While the idea of a brain RAS is provocative, 
uneven and nonoverlapping distributions of the brain RAS components have 
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caused skepticism (Brownfield et al., 1982; Moffett et al., 1987). A 
final possibility which circumvents the low brain levels of renin mRNA is 
that proposed by Ferrario et al. (1990), who suggested that angiotensin 
(1-7) is produced in the brain by an alternate enzymatic pathway. 
Angiotensin (1-7) produces an increase in vasopressin release, but not 
dipsogenic or vasoconstrictor activity. 
The RAS can respond within minutes to a sudden change in arterial 
pressure, while the aldosterone response to pressure changes may take 
hours to occur. The RAS is a relatively short-term pressure regulator. 
In normal kidneys, the renin-angiotensin system prevents wide fluctuations 
in arterial pressure, despite tremendous changes in salt intake (Guyton, 
1990). 
Long-term arterial pressure control is maintained by a renal-body 
fluid feedback mechanism. This means that as mean arterial pressure 
rises, the kidney will continue to excrete water and Na+ until the pressure 
is returned back to the original level or "set-point". It is thus 
considered to have "infinite gain" since the kidney will eventually return 
any pressure back to normal (Guyton, 1972). A large volume increase is 
necessary to elevate blood pressure acutely, while a small volume is 
needed to chronically raise pressure (Guyton, 1990). 
A pathological elevation in angiotensin results in Na+ and water 
retention. The increased Na+ concentration and fluid volume lead to 
increased arterial pressure. The resulting pressure diuresis maintains Na+ 
and body fluid balance (Hall et al., 1986). Thus if an animal is 
experimentally salt loaded, and angiotensin levels are maintained, 
hypertension will develop. How could renin stay elevated chronically? 
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First, by low renal blood flow (such as produced by a stenos is), and 
second by factors affecting water and electrolytes beyond the macula 
densa, presumably in the caudal distal tubule (Guyton, 1990). In 
essential hypertension, the output of the kidneys is normal, in the face 
of arterial pressures that are abnormally high. The reason for this 
abnormal renal function is completely unknown. 
Renin-Angio~ensin and Hyper~ension 
Hypertension is defined as any pressure above a systolic of 140 mm Hg, 
or a diastolic of 90 mm Hg. 60 million people suffer from high blood 
pressure (Ferrario, 1990). The etiology of pathogenic hypertension 
remains unknown for the majority of cases, termed essential hypertension. 
Due to the complex regulatory mechanisms involved in maintenance of 
arterial pressure (RAS, sympathetic nervous system, baroreceptors, 
chemoreceptors, renal fluid volume) it is very likely that many factors 
will have to be considered as causative. 
considered a family of diseases. 
Thus • hyper tens ion may be 
It is not surprising then, to discover that the sodium-renin profile 
of patients suffering from essential hypertension covers a wide spectrum. 
A certain percent have low renin values, which would be expected with 
elevated blood pressure. But 30% have high renin values, which is 
unexpected. In addition, 30% have "normal" renin values, which in the 
face of abnormally high blood pressure, may not be normal after all 
(Laragh, 1978). Experimentally, this corresponds to a rat model termed 2-
kidney, 1-clip, where a silver clip is placed on one renal artery, 
inducing an unnaturally low pressure in the clipped kidney. This kidney 
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produces excessive amounts of renin, although sodium and water excretion 
remain normal, since the remaining kidney is perfectly functional. In 
this model, converting enzyme inhibitors are highly effective at lowering 
the induced hypertension caused by the elevated plasma renin levels 
(Laragh, 1978). Clinically, this model could represent a stenotically 
injured renal artery, or other vascular injury to the kidney. A recent 
report has now shown that high renin-sodium profiles correlate 
significantly with future risk of heart attack (Alderman et al., 1991). 
If more than one factor is necessary for the development of 
hypertension, it is likely that more than one gene is involved. In Dahl 
salt-sensitive rats and spontaneously hypertensive rats (SHR) at least 
four independently segregating loci have been estimated to contribute to 
their hypertension (Morris, 1991). It has also been shown that 
restriction fragment length polymorphism marking the renin gene of the SHR 
was associated with their elevated blood pressure, suggesting that a 
structural defect in the renin gene, or a closely linked gene may be 
responsible for producing hypertension in SHR (Kurtz et al., 1990). 
The contribution of the renin-angiotensin system to the pathogenesis 
of some forms of hypertension is now well documented (Hall et al., 1986; 
Laragh, 1978; Shibutani et al., 1988; W"aeber et al., 1986). In rats, 
there is evidence that chronic angiotens in infusion and other 
manipulations which increase plasma renin activity cause hypertension 
(Reid, 1984). The onset of several forms of renin-dependent hypertension 
is dependent on structures in 
(Brody, 1988). PVN ablation 
the brain, 
in young 
primarily the hypothalamus 
SHR attenuated the normal 
development of their hypertension (Ciriello et al., 1984). 
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That the RAS contributes to maintaining hypertension is also evidenced 
by the effectiveness of intervening at different points of the system: 
renin, converting enzyme or ANG II. Direct inhibition of renin has two 
important advantages. Renin is the rate limiting enzyme and is substrate 
specific. Unfortunately, drug developers have yet to design an orally 
effective renin inhibitor (Corvo! et al., 1990; Weber et al., 1990). A 
peptide analog of ANG II, saralasin, has been developed that directly 
antagonizes ANG II receptors. However, it suffers from the same 
disadvantage as renin inhibitors: lack of oral activity. Both saralasin 
and renin inhibitors are effective depressor agents when administered iv. 
By far the most efficacious RAS antagonists are the converting enzyme 
inhibitors, such as captopril and enalapril, which are extensively used as 
treatments for essential hypertension (Waeber et al., 1986; Laragh, 1978). 
Considerable attention has been given ta the possible contributions 
tissue RAS may have in producing hypertension. Thus, paracrine or 
autocrine actions of ANG II may be important in cardiovascular regulation. 
For example, adrenal RAS has been found to augment aldosterone release in 
stroke prone SHR (Kim et al., 1991). Local generation of cardiac ANG II 
aggravated arrhythmias (Becker et al., 1989; Hirsch et al., 1990). The 
existence of a putative brain RAS, has spurred intensive research on the 
role it may play in the pathogenesis of hypertension (Ferrario, 1990). 
The ventrolateral medulla may be a central site of action for ANG II 
regulation of blood pressure. ANG II was found ta have a depressor action 
if injected into the caudal ventrolateral medulla, while injection of ANG 
II into the rostral ventrolateral medulla produced a pressor response 
(Sasaki and Dampney, 1990). 
14 
However, as discussed above, ANG II receptors have been identified in 
the circumventricular organs which lie outside the blood brain barrier, 
yet maintain synaptic connections with cardiovascular regulatory centers. 
Thus the subfornical organ, OVLT, and the area postrema may be mediating 
the effects of blood borne ANG II produced systemically (Brody, 1988). 
Electrolytic lesions in each of these structures produces a decrease of 
blood pressure in experimental hypertension (Moffett et al., 1987; Hartle 
and Brody, 1984). 
The pathogenesis of essential hypertension remains unknown, and a 
continued source of intensive investigations. From the brief review 
presented here, it is clear that the RAS is an important component of 
normal arterial pressure regulation. It would not be surprising if an 
abnormality of the RAS proved to be a consequential factor either for the 
development or maintenance of some forms of essential hypertension. 
Renin Regula~ion 
Granulated renin secreting cells are found throughout the kidney 
vasculature, with highest concentrations in the cells proximal to the 
glomerulus (Hackenthal et al., 1990). These juxtaglomerular cells are 
actually metaplastically transformed arteriolar smooth muscle cells, 
having reduced myofilaments (Churchill, 1988; Kurtz, 1990). If rats are 
chronically treated with converting enzyme inhibitors or salt deprived, it 
was found that additional smooth muscle cells are recruited to become 
renin secreting cells, as evidenced by elevated renin mRNA levels (Gomez 
et al., 1990). PCR (polymerase chain reaction) techniques have enabled a 
rough comparison of renin mRNA in various tissues. The conclusion reached 
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at this point is that there is relatively little renin mRNA in any tissue 
other than the kidney. For example, the adrenal had 0.3 to 1%, the heart 
and aorta 0.2%, the hypothalamus 0.1%, the liver 0.1% and the pituitary 
0.01% of that found in the kidney (Lou et al., 1991; Okura et al., 1991). 
However, these minute amounts could still be the minimum necessary for a 
functional autocrine or paracrine role in local RAS's (Hackenthal et al., 
1990). 
Synthesis of renin follows a standard pathway for secretory 
substances. Renin mRNA is translated into preprorenin, then glycosylated 
on the Golgi apparatus to form prorenin and packaged into granules where 
it undergoes final activation to renin (Vallotton, 1987). Renin gene 
expression is regulated, rather than being tonically turned on or off in 
a constitutive manner. There are excess renin stores in the kidney for 
several days. As discussed briefly in the RAS section, renin release is 
controlled by four primary mechanisms. These are: 1. stretch, 2. Na+ load, 
3. hormones, and 4. the sympathetic nervous system. Each of these will be 
examined individually. 
Stretch receptors. Renin secretion can be stimulated by a fall in 
blood volume or blood pressure. Hodge et al. (1966) discovered that a 
decrease in blood volume due to hemorrhage could cause ANG II elevations, 
independent of BP. Decreased renal perfusion pressure produces a decrease 
in internal ca++ via prostacyclin (PGI2 ) and cAMP (Jackson, 1991). When 
renal blood pressure or blood volume are elevated, it is presumed that 
renal "stretch" receptors are activated, which cause an increase in ca++ 
influx, resulting in renin inhibition (Kurtz et al., 1990). Although 
still under investigation, the putative renal "stretch" receptor may 
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actually be the j uxtaglomerular cell itself. No other site has been 
proposed, and since the juxtaglomerular cells are transformed smooth 
muscle cells, it is easy to envision a transduction mechanism involving 
myofilaments responsive to distension. 
Macula densa mechanism. Renin secretion can be stimulated by reduced 
levels of Na+ sensed by the macula densa cells located on the distal 
tubule, adjacent to the afferent arteriole and glomerulus. This close 
proximity originally led investigators to propose that these cells could 
act as chemical sensors (Vander, 1965). Only a 10% drop in plasma Na+ can 
result in a 400% increase of renin secretion. In contrast, a 10% increase 
in plasma Na+ causes just a 60% reduction in renin (Kurtz et al., 1990). 
The actual signal transmitted from the macula densa to the renin 
secreting juxtaglomerular cells remains subject to debate. Two distinct 
theories exist to explain the phenomenon of tubuloglomerular feedback. 
The first suggests that ionic changes in the interstitial medium between 
the macula densa and juxtaglomerular cells are "sensed" by cell surface 
receptors on the juxtaglomerular cells. In this theory, either Na+, c1-
or both are the chemical signal (Navar et al., 1991; Persson et al., 
1991). Most evidence favors c1- as the actual signal to inhibit renin 
secretion (Hackenthal et al., 1990). The second theory proposes that 
energy dependent uptake of Na+ releases adenosine as a metabolic product 
from the macula densa. This excess of adenosine activates high affinity 
A1 receptors on the juxtaglomerular cells to increase the internal Ca ++ 
concentration, and thereby inhibit renin secretion (Jackson, 1991). 
Hormones. There are a number of hormones capable of either increasing 
or decreasing renin release. The primary hormone influencing renin is the 
final product of the synthetic pathway, ANG II. 
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ANG II tonically 
inhibits renin secretion via three negative feedback loops: a) directly to 
the juxtaglomerular cells, b) through vasoconstriction, ANG II elevates 
blood pressure, which is an inhibitory signal, and c) ANG II stimulates 
aldosterone to conserve Na+, which is also an inhibitory signal (Kurtz, 
1990). Chronic ANG II infusion results in a decrease in renin mRNA levels 
demonstrating regulation of renin gene expression (Johns et al., 1990). 
As with the other hormonal messengers, ANG II produces an influx of ca++, 
which functions as the inhibitory second messenger. 
Other hormonal substances can also alter renin secretion. Adenosine 
is known to inhibit renin secretion and may mediate signals from the 
macula densa, as described above, in an autocrine fashion (Jackson, 1991). 
Atrial natriuretic peptide (ANP) produces vasodilation, increases Na+ 
excretion, increases glomerular filtration rate and inhibits renin 
secretion (Atlas et al., 1986). However, it is probably not as important 
an influence as originally expected, since physiologic doses of ANP did 
not alter arterial pressure or PRA (Kivlighn et al., 1990; Hackenthal et 
al., 1990). Vasopressin has an inhibitory influence on renin secretion, 
but is not a primary regulatory hormone (Hackenthal et al., 1990). Each 
of these hormones decreases renin release by raising intracellular levels 
of ca++ concentration. 
Sympathetic nervous system. While the signals discussed thus far are 
predominantly negative, increased sympathetic nerve activity will raise 
plasma renin levels. This is done predominantly through norepinephrine 
release and activation of renal p1 receptors (Hackenthal et al., 1990). 
However, some evidence also suggests a positive involvement of renal a 
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receptors and extrarenal Preceptors (Blair et al., 1991). 
Besides the sympathetic nervous system, other forms of central 
regulation of renin release have been investigated. Ueda et al. (1967) 
were the first to stimulate the brain and see an increase in renin 
release. In their studies, electrodes were placed in the midbrain, just 
dorsal to the central gray, and PRA increased even in renal denervated 
dogs. Thus, factors in the brain other than the sympathetic nerves are 
capable of elevating renin release. Lesions in the PVN with a selective 
catecholamine neurotoxin inhibited stress-induced elevations of PRA and 
PRC (Richardson Morton et al., 1990). Histamine antagonists injected into 
the ventricles of the brain inhibited restraint-induced increases in PRA, 
while injection of histamine !CV increased PRA (Matzen et al., 1990). 
Electrical stimulation of different brain sites can cause renin release. 
Stimulation of the PVN (Porter, 1988) and ventrolateral medulla, as well 
as lesions in the anteroventral third ventricular (so called AV3V) region 
result in elevated PRA (Brosnihan and Ferrario, 1984). Electrolytic 
lesions in nuclei within the hypothalamus result in blunting of the renin 
response to a variety of stimuli, including low Na+ diet, head-up tilt, 
immobilization and PCA (Gotoh et al., 1987; 1988). In addition, there is 
evidence for a blood borne renin releasing factor produced by the 
hypothalamus (Urban et al., 1985). Hypothalamic extracts significantly 
elevated renin secretion from in vitro kidney slices (Van de Kar et al., 
1987). These studies suggest that structures within the brain may have a 
prominent influence on renin regulation. As previously mentioned, the 
circumventricular organs which lie outside the blood brain barrier, are 
heavily labeled autoradiographically with [125I]ANG II or its antagonist 
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[125I] saralasin (van Houten et al., 1980; Mendelsohn et al., 1990). If the 
brain does have an important role in renin regulation, a necessary form of 
communication from the kidney back to the brain should exist. Since the 
circumventricular organs contain ANG II receptors, they are in an ideal 
position to monitor this feedback control. Furthermore, the area 
postrema, subfornical organ and OVLT maintain direct connections with the 
PVN, a likely integrator of renin regulation within the hypothalamus (Lind 
et al, 1985; Van de Kar et al., 1990). 
The exocytotic mechanism of renin secretion is still unclear. In 
normal smooth muscle cells, an increase in intracellular calcium causes an 
increase in contraction. In other endocrine or transmitter secreting 
cells, release is also dependent on calciU111 entry. However, in 
juxtaglomerular cells a decrease in internal ca++ concentration stimulates 
renin release. This inverse relationship with ca++ has become known as the 
ca++ paradox. It has been postulated that all signals regulating renin 
secretion do so by either increasing or decreasing intracellular ca++ 
levels (Fray, 1990). For example, a decrease in extracellular ca++ in 
isolated perfused kidneys reduces renin secretion. Conversely, elevated 
renal perfusion pressure causes an increase in stretch and an increase in 
ca++ influx, causing a decrease in renin secretion (Fray, 1990). Decreases 
in intracellular ca++ have been shown to cause renin secretion, independent 
of cAMP changes (Pardy et al., 1989). Cell surface receptors are linked 
through stimulatory (G5 ) or inhibitory (G1) G-proteins to adenylate cyclase 
or to phospholipase C. In juxtaglomerular cells, cAMP acts as a 
stimulatory second messenger, while cGMP acts as an inhibitory second 
messenger (Della Bruna et al., 1991). How these second messengers relay 
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their stimulatory or inhibitory signals to renin containing granules 
remains a mystery. 
In summary, stimuli that augment renin secretion appear to do so by 
increasing intracellular levels of cAMP. These are norepinephrine from 
sympathetic terminals or epinephrine from the adrenal which activate p1 
receptors and cAMP; a decrease in perfusion pressure stimulating 
prostacyclin and elevating cAMP; and a decrease in Na+ at the macula densa, 
which also activates prostacyclin and cAMP (Jackson, 1991). Factors which 
inhibit renin secretion may all act to increase internal ca++ levels in the 
juxtaglomerular cells. These signals include the hormones ANG II, 
vasopressin, atrial natriuretic peptide, adenosine, and increases in 
plasma volume, arterial blood pressure and distal tubule sodium load 
(Fray, 1990). 
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Serotonin 
Serotonin Pharmacology 
History. 5-Hydroxytryptamine (5-HT) was discovered by Page as a 
vasoconstrictive substance in serum, derived from platelets, and thus the 
name serotonin (Rapport et al., 1947). In Italy, Erspamer had identified 
a vasoconstrictive substance derived from enterochromaffin cells of the GI 
tract he termed "enteramine", which was soon recognized to be identical to 
serotonin. By 1953, Page had detected 5-HT in the brain, so that by the 
early 1950's serotonin was isolated from the three major depots in the 
body: the gut, platelets, and the brain (Sjoerdsma and Palfreyman, 1990). 
Early pharmacological investigations concentrated on possible 
antihypertensive agents, but soon moved towards emotional disorders such 
as depression and anxiety when the psychoactive ergot LSD was recognized 
to have a structure containing a serotonin backbone. The efficacy of 
tricyclic antidepressants and 5-HT uptake inhibitors developed during the 
early 1970's, instigated the formulation of the serotonergic hypothesis of 
depression (Van de Kar, 1989). 
Biochemistry. The precursor for 5-HT is the essential amino acid L-
tryptophan, the availability of which is usually rate limiting. The 
biosynthesis of 5-HT involves only two enzymes, the first of which is rate 
limiting. Tryptophan hydroxylase generates 5-hydroxytryptophan, which is 
decarboxylated by L-aromatic amino acid decarboxylase, to produce the 
final product 5-hydroxytryptamine. Storage of 5-HT occurs in granules of 
all cells which secrete 5-HT. Release of 5-HT is a ca++ dependent process. 
Once released, the primary mode of inactivation is by a presynaptic high 
affinity reuptake transporter specific for 5-HT. 
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5-HT is degraded by 
monoamine oxidase and aldehyde dehydrogenase to produce the metabolite 5-
hydroxyindole acetic acid (Grahame-Smith, 1988). Enterochromaffin cells 
of the gut contain greater than 90% of the body's 5-HT. Platelets do not 
synthesize 5-HT, but rather utilize the active uptake mechanism. 
Substance P often coexists with 5-HT in brain and gut 5-HT granules, 
although the function of this is not yet known (Tyce, 1990). Other 
peptides and their receptors have been identified in the raphe nuclei, 
including CCK (cholecystokinin), TRH (thyrotropin releasing hormone), 
neurokinin A, and enkaphalin, although their functions are currently 
unknown (Paris and Lorens, 1989; Boden et al., 1991; Cooper et al., 1991). 
Receptor types. Two peripheral receptors were initially characterized 
based on differential agonist potencies, and termed "M" and "D" receptors. 
D receptors contracted smooth muscles, while M receptors depolarized 
cholinergic nerves (Grahame-Smith, 1988). A seminal report in 1979 by 
Peroutka and Snyder categorized brain 5-HT receptors as belonging to two 
major "families", the 5-HT1 or 5-HT2 subtypes. This classification was 
based, by definition, on high affinity (nanomolar) binding of 5-HT to 5-HT1 
receptors, and low affinity (micromolar) of 5-HT binding to 5-HT2 receptors 
(Hamon et al., 1990). High affinity agonists were quickly developed for 
5-HT1 receptors and high affinity antagonists developed for 5-HT2 
receptors. Other receptor subtypes were rapidly characterized so that 
currently there are six well recognized receptors: 5-HT1A, 5-HT1B, 5-HT1c, 
5-HT10 , 5-HT2 and 5-HT3 (Frazer et al., 1990). Binding studies have 
revealed potentially a 5-HT1E, and a 5-HT4 receptor subtype (Hamon et al., 
1990; Bockaert et al. , 1990). The previously identified "D" receptor 
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appears to correspond to the 5-HT2 receptor, while the "M" receptor was 
renamed the 5-HT3 receptor (Frazer et al., 1990). 
Amino acid sequences, G-protein linkage, and second messengers are 
being characterized for each of the 5-HT receptors using molecular 
biological techniques (Hartig et al., 1990). Clones have been produced 
for 5-HT1A, 5-HT1a110 , 5-HT1c and 5-HT2 subtypes, revealing each to contain 
7 membrane spanning domains routinely seen with G-protein coupled 
receptors. Interestingly, the sequence homology between the 5-HT1c and 5-
HT2 subtypes is greater than 70%, suggesting they are actually members of 
the same family. These two receptors also share the same G-protein 
stimulated second messenger system, namely phosphoinositol turnover (Conn 
and Sanders-Bush, 1987). The remaining S-HT1 receptors are all coupled via 
G1 , to adenylate cyclase. Evidence suggests that 5-HT3 receptors are part 
of an ion channel (Aghajanian et al., 1990). 
Anatomy. 5-HT neuronal cell bodies were first localized to the 
midbrain using histofluorescence (Dahlstrom and Fuxe, 1965). These were 
grouped into nine clusters of cells, labeled Bl through B9. These can 
easily be divided into two major groups, caudal (comprising Bl-B3) and 
rostral (comprising B4-B9). Immunohistochemical use of 5-HT antibodies 
allowed for detailed mapping (Tork, 1990). The caudal cell groups send 
most of their projections to the spinal cord, while the middle cell groups 
(B4-B6) send diffuse projections throughout the brainstem and cerebellum. 
The more rostral nuclei include the median (B8) and dorsal raphe (B7), 
which send projections to cortical areas containing limbic structures 
(amygdala and hippocampus), as well as the hypothalamus (Azmitia and 
Segal, 1978). 
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Recent advances in autoradiography have enabled the precise 
localization of the different receptor subtypes in various brain regions 
(Palacios et al., 1990; Radja et al., 1991). 5-HTu. receptors are found 
in the neocortex and the limbic structures, hippocampus, septum, amygdala 
and hypothalamus (Pazos and Palacios, 1985). 5-HTu autoreceptors are 
located on dorsal raphe cell bodies (somato-dendritic receptors, Gothert 
and Schlicker, 1990). The 5-HT1B and 5-HT1D receptors can be localized to 
basal ganglia structures such as the striatum, substantia nigra, and 
pallidum. These receptors are ostensibly the same receptor, although 
there is a species differentiation, with the 5-HT1B subtype appearing in 
mice and rats, and the 5-HT10 subtype appearing in humans and all other 
species studied thus far (Waeber et al., 1989). Some evidence suggests 
that this subtype is a presynaptic autoreceptor (Gothert and Schlicker, 
1990), although the evidence is not conclusive. The 5-HT1c receptor has 
been found in high concentrations in the choroid plexus, where it is 
believed to regulate cerebral spinal fluid volume and composition (Pazos 
and Palacios, 1985). The 5-HT2 receptor has been visualized in the frontal 
cortex, nucleus accumbens, and the hypothalamus (Pazos et al., 1985). 
Peripherally, 5-HT2 receptors have been localized to smooth muscle and 
platelets (Leysen and Pauwels, 1990). 5-HT3 receptors have only just been 
found in the brainstem in such places as the area postrema, where they may 
link the periphery with the brain (Cooper and Abbott, 1988). 
Functions. An early description of behavioral effects attributed to 
5-HT is known as the "serotonin syndrome". In rats, it is characterized 
by hindlimb abduction and rigidity, forepaw treading, lateral headweaving 
and tremor (Frazer et al., 1990). Humans have experienced restlessness, 
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shivering and mental confusion (Sternbach, 1991). This hyperstimulation 
of the 5-HT system has been attributed to activation of 5-HTlA receptors 
in the spinal cord. 
5-HT is considered to play a role in a wide variety of behavioral and 
homeostatic functions: anxiety (Taylor, 1990; Chopin and Briley, 1987), 
depression (Meltzer, 1990), panic disorder (Den Boer and 'Westenberg, 
1990), sex, 
compulsive 
sleep and thermoregulation (Glennon, 
disorder (Murphy, 1990), appetite 
1987), obsessive-
(Leibowitz, 1990), 
schizophrenia and hallucinations (Leysen and Pauwels, 1990; Glennon et 
al., 1982), migraine (Humphrey et al., 1990), pain (Sternbach, 1991), 
emesis (Cooper and Abbott, 1988), memory (McEntee and Crook, 1991) and as 
a growth factor (Seuwen and Pouyssegur, 1990). These functions are often 
associated with different receptor subtypes, which correlate with their 
anatomical location. 
Many hormones have been found to be stimulated by serotonergic agents. 
The current status of neuroendocrine function and receptor subtype 
regulation consists of: ACTH and corticosterone with 5-HTlA or 5-HT1c/5-HT2 
(Fuller, 1990; Cowen et al., 1990); prolactin with 5-HT1B or 5-HT1c/5-HT2 
(Cowen et al., 1990; Van de Kar, 1991); oxytocin and vasopressin with 5-
HT1c/5-HT2 (Saydoff et al., 1991; Brownfield et al., 1988). 5-HT receptor 
types regulating renin secretion are discussed fully below. 
Drugs. This plethora of receptor subtypes has been utilized by drug 
developers to design an expanding array of agents, aimed at relieving 
different ailments attributed to a specific S·HT receptor related 
dysfunction (Gothert and Schlicker, 1990; Sjoerdsma and Palfreyman, 1990). 
The 5-HT uptake inhibitor fluoxetine is widely marketed as an 
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antidepressant. The 5-HTlA agonists buspirone and ipsapirone are used as 
anxyiolytics. The 5-HT10 agonist sumatriptan is used in migraine therapy. 
5-HTz antagonists may prove therapeutic for anxiety, schizophrenia and 
sleep disorders. Ondansetron and zacopride, 5-HT3 antagonists, are 
established therapeutic antiemetics for cancer chemotherapy-induced 
vomiting. The list of potentially useful serotonergic drugs is as long as 
ailments attributed to 5-HT dysfunction. Clearly, investigation of the 
multiple roles that brain 5-HT plays is necessary for integrative 
understanding, and development of further drugs. For a complete list of 
the agents used in this dissertation study, please refer to page xi. 
Imporcance of Seroconin in Cardiovascular Diseases 
Serotonin, derived from platelets, was originally isolated because of 
its vasoconstrictor actions. However, central actions of 5-HT may prove 
to be more relevant physiologically in the pathogenesis and maintenance of 
hypertension. 
Studies have shown that 5-HT may be an important component of CNS 
cardiovascular regulation (Mikulic et al., 1988; Ramage, 1988; Robinson et 
al., 1985; Smits et al., 1978). Direct injection of 5-HT into the 
anterior hypothalamus and electrical stimulation of the dorsal raphe 
produce acute pressor effects in both SHR and their normotensive controls, 
Wis tar Kyoto rats (Wolf et al., 1981). Recent evidence suggests that 5-HT2 
receptors may be involved in BP regulation (Kushiro et al., 1988). 5-HT2 
receptors are located on vascular smooth muscle and platelets. Thus, 5-HT 
can augment or reduce blood flow depending on multiple variables including 
vascular bed, sympathetic tone, dose and route of administration (Van 
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Neuten et al., 1985). 
Injection of 5-HT elicits complex changes in the cardiovascular 
system. A triphasic response pattern occurs, attributable to activation 
of different receptor subtypes in different locations. Initially, there 
is a depressor response thought to be due to immediate bradycardia and 
lowered cardiac output mediated by 5-HT3 receptors. Subsequently, 5-HT2 
receptors are considered to produce an increase in total peripheral 
resistance, an increase in cardiac output and an increase in blood 
pressure. Finally, a long lasting depressor response occurs mediated by 
5-HT1 receptors (Saxena and Villalon, 1990; Dabire et al., 1990). The 5-
HT1 depressor response is considered to be due to a central decrease in 
sympathetic nerve activity, an increase in vagal activity, a decrease in 
transmitter release from sympathetic terminals, and a decrease in 
peripheral resistance (Dabire and Richer, 1991). 5-HT4 receptors may have 
a direct inotropic effect on the heart (Saxena and Villalon, 1991). The 
overall response pattern of 5-HT agonists appears to be that 5-HTlA 
agonists produce vasodilation and hypotension, while 5-HT2 agonists are 
vasoconstrictors causing hypertension, but many mixed response patterns 
result from dose, route and site of administration. 
There is some evidence that 5-HT may contribute to the development of 
hypertension in SHR. An increased availability of tryptophan produced 
SHRs with higher blood pressure (Kubo et al., 1990). Intra-arterially 
injected 5-HT augmented cerebral arterial vasoconstriction in stroke-prone 
SHR (Mayhan and Faraci, 1990). Presumably, this 5-HT would derive 
endogenously from platelets, and has implications for stroke and cerebral 
vascular diseases. 
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Stimulation of serotonergic neurons in the dorsal raphe nucleus and 5-
HT receptive cells in the anterior hypothalamus increases blood pressure 
both in normotensive and hypertensive rats (Kuhn et al., 1980; Smits et 
al., 1978; Wolf et al., 1981). Direct injection of 5-HTlA agonists 8-0H-
DPAT and flesinoxan into the dorsal raphe produced hypotension and 
bradycardia (Connor and Higgins, 1990). Intracisternal administration of 
the serotonin selective neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) 
produced a 10 mm Hg drop in BP 10 days after treatment in rats (Mikulic et 
al., 1988). 5-HT turnover in the hypothalamic paraventricular and 
supraoptic nuclei and in the median eminence is elevated in SHR (Koulu et 
al., 1986a). In addition, 5-HT turnover is elevated in the raphe nuclei 
during the development of hypertension in young SHR (Koulu et al., 1986b). 
These studies suggest that 5-HT from the dorsal raphe may be involved in 
the pathogenesis of some forms of hypertension. 
There appear to be opposing actions of 5-HT1A and 5-HT2 agonists on the 
ventral surface of the medulla. When applied to the ventral surface of 
the medulla, the 5-HT1A agonists 8-0H-DPAT or urapidil dose-dependently 
cause hypotension and inhibit sympathetic nerve discharge in anesthetized 
cats (McCall et al., 1987; Gillis et al., 1989; McCall et al., 1989; 
Mandal et al., 1990b). However, the 5-HT2 agonist DOI (±-1- [ 2, 5-dimethoxy-
4-iodophenyl] -2-aminopropane HCl) causes an increase in blood pressure, 
with no accompanying bradycardia, and an increase in sympathetic nerve 
discharge (McCall and Harris, 1988; Mandal et al. , l 990a; King and 
Holtman, 1990). Finally, stimulation of cardiac vagal afferents 
specifically decrease 5-HT turnover in hypothalamic and brain stem nuclei 
during acute myocardial ischemia and after coronary artery occlusion (Sole 
29 
et al., 1978; 1983). 
There are two possible mechanisms whereby 5-HTlA agonists could lower 
blood pressure: either by 5-HTlA autoreceptor inhibition of dorsal raphe 
neurons, or by 5-HT1A postsynaptic inhibition of medullary sympathetic 
neurons. It may be that central 5-HTlA receptors play a more important 
role than peripheral 5-HT2 receptors in cardiovascular regulation. 
Increased vascular reactivity to 5-HT in hypertensives is considered more 
of a general phenomenon than specific for 5-HT. Although other 5-HT2 
antagonists such as ritanserin and LY53857 are ineffective as 
antihypertensive agents (Van Zwieten et al., 1990), the selective 5-HT2 
antagonist ketanserin is being used clinically as an anti-hypertensive 
drug (Van Heuven-Nolsen, 1988). Evidence now suggests that ketanserin is 
also a relatively potent a 1 antagonist (Koss, 1991), but additional 
antihypertensive action could be due to blocking 5-HT2 receptors on 
vascular smooth muscle. Thus the interaction between platelet derived 5-
HT and vascular 5-HT2 receptors would be interrupted, reducing the 
vasoconstrictive action of 5-HT in the blood (De Clerck, 1991). 
Therefore, the results of the experiments from this dissertation 
project may lead to further understanding of hypertension, development of 
more specific anti-hypertensive drugs, and an increased ability to 
manipulate the systems implicated in these disease states. 
Recep~or Sub~ype Hedia~ing Renin Release 
Our previous data suggest that activation of 5-HTz receptors increases 
renin secretion. The 5-HT1c/5-HT2 antagonist LY53857 blocked the increase 
in renin levels caused by injection (ip) of the nonselective 5-HT agonist 
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MK-212 and 5-HT releaser fenfluramine, while other selective 5-HTlA 
agonists, ipsapirone and 8-0H-DPAT, elevated plasma corticosterone but not 
renin levels (Lorens and Van de Kar, 1987). The mixed 5-HTlA/lB agonist RU 
24969 (ip) elevated PRA, PRC, ACTH, and plasma corticosterone and 
prolactin. Only the RU 24969-induced increases in PRA and PRC were 
inhibited with the 5-HT2 antagonists LY53857 and ritanserin (Van de Kar et 
al., 1989), suggesting that RU 24969 may also interact with 5-HT2 
receptors. This differential control of hormonal release suggests that 
the serotonergic stimulation of renin release is mediated by 5-HT2 
receptors. 
Some dispute exists concerning the separate identity of 5-HT1c and 5-
HT2 receptors, since both are coupled through G proteins to 
phosphoinositide hydrolysis, and they display similar affinities for a 
variety of drugs (Hoyer, 1988). 5-HT1c receptors are primarily located in 
choroid plexus (Conn and Sanders-Bush, 1987), although low levels of mRNA 
for the 5-HT1c receptor have been identified in the hypothalamus (Mengod 
et al., 1990). 5-HT2 receptors are found in the cerebral cortex and 
hypothalamus (Appel et al., 1990). Since the antagonist spiperone has a 
100-fold greater affinity for 5-HT2 receptors than 5-HT1c receptors (Hoyer, 
1988), it provides the best drug currently available to differentiate 
between 5-HT1c and 5-HT2 receptor mediated renin secretion. 
Other studies have also suggested that renin secretion is mediated via 
5-HT2 receptors. The nonselective 5-HT agonist quipazine injected iv 
increased PRA in a dose-dependent manner, which was blocked by 5-HT2 
antagonists (Alper and Snider, 1987). However, it was determined that 
this increase in PRA may have been secondary to a decrease in renal blood 
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flow (Zink et al., 1990). The 5-HT1c/5-HT2 agonist DOI increased PRA when 
injected iv, although this also was attributed to a decrease in renal 
blood flow (Alper, 1990a). Finally, the nonselective 5-HT agonist m-
chlorophenylpiperazine (m-CPP) and DOI significantly elevated PRA, 
although no 5-HT2 antagonists were used to inhibit the response (Bagdy et 
al., 1992). 
As previously described, 5-HT can influence a host of hormones through 
differential receptor subtype regulation. Although other receptor types 
may be involved, studies reported thus far support the 5-HT2 receptor 
subtype as the primary serotonergic regulator of renin release from the 
kidney. Where those receptors are located remains a debate. 
Location of 5-HT Receptors Regulating Renin Secretion 
Peripheral. Intrarenal infusion of 5-HT into denervated dog kidneys 
resulted in elevated renin secretion (Takahashi et al., 1991). There was 
no accompanying change in blood pressure, but an initial decrease in renal 
blood flow could account for the renin release. This 5-HT-induced renin 
secretion was attenuated by the 5-HT2 antagonist ketanserin, suggesting 
that 5-HT2 receptors within the kidney could be responsible for 
serotonergic stimulation of renin release. 
Several 5-HT agonists increase PRA in a dose-dependent manner upon ip 
administration to conscious rats. The 5-HT1 agonist m-CPP (Saydoff et al., 
1989), the 5-HTlA/5-HTlB agonist RU 24969 (Van de Kar et al., 1989), the 5-
HT1/5-HT2 agonist MK 212 (Lorens and Van de Kar, 1987) all elevated PRA in 
a dose-dependent manner. When the 5-HT releasing drug PCA was 
administered ip, renin secretion was also stimulated in a dose-dependent 
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manner (Van de Kar et al., 1981). 
Systemic injection of the 5-HT releaser PCA and the 5-HT2 agonist 
quipazine elevated arterial pressure and plasma renin activity (PRA), 
while reducing heart rate and renal blood flow (Alper and Snider, 1987; 
Alper et al., 1987). Administration of quipazine iv produced 
cardiovascular changes (hypotension followed by hypertension) mediated by 
peripheral and central 5-HT2 receptors (Vayssettes-Courchay et al., 1990; 
Vayssettes-Courchay et al., 1991). The 5-HT2 agonist DOI also increased 
blood pressure and decreased renal blood flow when administered iv. These 
responses were abolished by the 5-HT2 LY53857 as well as by the 5-HT 
antagonist xylamidine which does not readily cross the blood brain barrier 
(Alper, 1990a). However, direct infusion of DOI into the kidney resulted 
in renal vasodilation and an increase in renal blood flow (Shoji et al., 
1990), suggesting DOI may act directly at the kidney to stimulate renin 
secretion. 
Central. Central administration of 5-HT into the ventricles (ICV) 
produces a biphasic blood pressure response. An initial rise within 5 
minutes is followed by a longer lasting hypotensive response (Stein et 
al., 1987; Montes and Johnson, 1990). Additionally, 5-HT injected !CV 
stimulates Na+ excretion from the kidney, suggesting that 5-HT may produce 
its effects on renin secondarily to elevated Na+ excretion (Stein et al., 
1987). 
The elevation of PRA following RU 24969 is potentiated when 
serotonergic neurons are destroyed by !CV administration of the 5-HT 
selective neurotoxin 5,7-DHT (Van de Kar et al., 1989). These results 
suggest that stimulation of 5-HT receptors in the brain increase PRA and 
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PRC and that these receptors can be made supersensitive when serotonergic 
neurons are destroyed. Thus, the postsynaptic 5-HT receptors, unaffected 
by the toxic effects of presynaptic 5,7-DHT uptake, become functionally 
up-regulated in response to the diminished input from the damaged 
presynaptic 5-HT terminals. Intra-PVN injection of RU 24969 significantly 
elevated PRA, suggesting that 5-HT receptors in the PVN are involved in 
the control of renin secretion. The dose of RU 24969 (10 µg/kg) was 50-
fold lower than the minimally effective ip dose of 0.5 mg/kg (Van de Kar 
et al., 1990). 
ICV administration of PCA (400-600 µg/rat) caused dose-dependent 
increases in sodium excretion and blood pressure (Stein et al., 1987). 
This suggests that CNS mechanisms may be involved in regulating renal 
function via 5-HT neurons. Previous pharmacological studies showed that 
pretreatment of rats with the synthesis inhibitor p-chlorophenylalanine 
(PCPA, ip) prevented PRA elevations following PCA injection (ip). 5,7-DHT 
administered ICV 14 days prior to sacrifice also significantly reduced PRA 
from basal levels. This demonstrates that serotonergic neurons in the 
brain can stimulate renin release from the kidneys (Van de Kar et al., 
1981). Destruction of 5-HT neurons in the dorsal raphe nucleus with 5,7-
DHT also blocked the renin response to PCA (Van de Kar et al., 1982). 
Electrolytic lesions in the dorsal raphe blocked renin release due to the 
stressor of conditioned emotional fear (Van de Kar et al., 1984) and after 
injection of PCA (Gotoh et al., 1988). These experiments indicate that 5-
HT may be an important component of the neural control of renin release. 
The PCA induced elevation in PRA was also blocked by destroying the 
mediobasal hypothalamus (Karteszi et al., 1982). These studies suggest 
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that a serotonergic pathway originating in the dorsal raphe nucleus and 
terminating in the hypothalamus plays a role in increasing renin 
secretion. 
The search for the central site regulating renin release has 
subsequently focused on the hypothalamic paraventricular and ventromedial 
nuclei. The PVN has known neuroendocrine functions: vasopressin, CRF, 
TRH, and oxytocin secretory neurons are located there (Swanson and 
Sawchenko, 1983). Neuropeptide Y appears to play a prominent role in 
regulating feeding and energy balance through actions in the PVN 
(Leibowitz, 1991). The VMN may contain a "satiety center" (Tokunaga et 
al., 1986), and control thermoregulation (Amir, 1990) and sexual behavior 
(Schulze and Gorzalka, 1991). The PVN, VMN or both may be necessary 
regulatory components of the pituitary-adrenal axis vital to the stress 
response (Filaretov and Filaretov, 1985; Feldman et al., 1987). 
Electrical stimulation of the PVN increases PRA in a frequency dependent 
manner (Porter, 1988). Ablation of the PVN both electrolytically and with 
the cell-selective neurotoxin ibotenic acid, blocked the effects of stress 
on PRA, PRC, and plasma corticosterone concentration (Richardson Morton et 
al., 1989). Other studies have shown that the effect of PCA on PRA and 
PRC was blocked by electrolytic lesions in the VMN (Gotch et al., 1987). 
VMN ablation also attenuated the PRA and PRC response to low sodium diet, 
immobilization, and head-up tilt (Gotoh et al. , 1988). Hypothalamic 
extracts contain a renin-releasing factor which stimulated renin secretion 
from kidney slices in a dose dependent manner (Urban et al., 1985; Van de 
Kar et al., 1987). 
Taken together, these studies suggest that the hypothalamus, and 
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specifically the PVN or VMN, may contain 5-HT receptors that exert an 
important influence on renin secretion. Therefore, the experiments 
proposed for this dissertation were designed to characterize these sites. 
CHAPTER III 
EVIDENCE THAT DOI INCREASES RENIN SECRETION AND BLOOD 
PRESSURE THROUGH CENTRAL AND PERIPHERAL 5-HT RECEPTORS 
INTRODUCTION 
The present studies were undertaken to obtain clearer information 
concerning the identity and site of the 5-HT receptor subtype(s) that 
stimulate renin secretion (Alper and Snider, 1987; Zink et al., 1990; Van 
de Kar, 1991). Most of the evidence suggests that the 5-HT receptors 
stimulating renin secretion are located centrally (Van de Kar et al., 
1981; Van de Kar and Richardson-Morton, 1986; Van de Kar et al., 1989), 
and are 5-HT2 receptors (Alper and Snider, 1987; Van de Kar et al., 1989). 
However, there is a great similarity between 5-HT2 and 5-HT1c receptors and 
most drugs used so far have not distinguished between them. Furthermore, 
recent evidence suggests that peripheral 5-HT receptors can also stimulate 
renin secretion (Zink et al., 1990). Therefore, a closer examination of 
the 5-HT receptor subtype that regulates renin secretion was needed. 
DOI is a recent addition to the rapidly expanding arsenal of 5-HT 
agonists (Shannon et al., 1984; Glennon et al., 1982). DOI is a 5-HT1c and 
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s-HT2 agonist, which produces a number of cardiovascular and hormonal 
consequences. DOI elevates blood pressure and sympathetic nerve discharge 
when administered iv (McCall et al., 1987). However no concomitant 
alterations in heart rate were observed (McCall and Harris, 1988; Dabire 
et al., 1989). DOI also elevates plasma renin activity (Alper, 1990a) and 
plasma ACTH/corticosterone (Alper, 1990b; Calogero et al., 1989). A 
peripheral site of action may exist for DOI's effects on plasma renin 
activity and blood pressure (Alper, 1990a). However, Clement and McCall 
(1990) demonstrated that the ventrolateral medulla is the site of action 
of iv administered DOI-induced elevations of mean arterial pressure and 
sympathetic nerve discharge in anesthetized cats. Therefore, it remains 
unclear whether DOI' s effects on renin secretion via 5-HT1c/5-HT2 receptors 
involve only peripheral, or both peripheral and central sites of action. 
The present experiments were designed to investigate whether 5-HT1c, 
5-HT2 or some other receptor subtypes are involved in mediating the renin 
response to DOI. Furthermore, experiments were designed to determine 
whether the receptors are located predominantly in the brain, or in 
peripheral sites. For this purpose, selective 5-HT antagonists were 
tested on their ability to attenuate the renin and blood pressure response 
to DOI. The antagonists used were: ritanserin, a 5-HT1c/5-HT2 antagonist 
(Schotte et al., 1989; Van Nueten et al., 1986); spiperone, a 5-HT1A/5-
HT2/dopamine (D2) antagonist, which has about a 100-fold higher affinity 
for 5-HT2 receptors than 5-HT1c receptors (Hoyer, 1988; Goffinet et al., 
1990); and xylamidine, a 5-HT2 antagonist postulated to have primarily a 
peripheral site of action (Copp et al., 1967; Leysen, 1990). To 
distinguish different sites of action mediating the effects of DOI, we 
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injected DOI via two routes of administration: either peripherally into 
the femoral artery (ia) or centrally into the lateral cerebral ventricles 
(ICV). A decrease in blood pressure stimulates renin secretin through 
activation of a renal "stretch receptor" (Tobian et al., 1959). Because 
DOI has potent cardiovascular effects, blood pressure was measured to test 
whether the renin response to DOI was related to these changes. 
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METHODS 
Ani.JJJals 
Male Sprague-Dawley rats (27S-300g) were purchased from Sasco-King 
Animal Laboratories. The rats were housed 2 per cage in a climate and 
illumination-controlled room. Water and rat chow were available ad 
libitum. All experiments were conducted between 11:00 A.M. and 3:00 P.M. 
All protocols were approved by the Loyola University Institutional Animal 
Care and Use Committee. 
Drugs 
DOI was purchased from Research Biochemical Inc. (Natick, MA). 
Spiperone was purchased from Sigma (St. Louis, MO). Xylamidine was 
donated by Wellcome Research Laboratories (Beckenham, UK). Ritanserin was 
donated by Janssen Pharmaceutica (Belgium). 
Surgery 
Implantation of ICV cannulas and intrafemoral catheters was performed 
under pentobarbital anesthesia. Animals were pretreated with SO mg/kg 
ampicillin to prevent infection and 0.2 mg/kg atropine methyl bromide to 
reduce excessive secretions. The ICV cannulae (Plastics One, Roanoke, VA) 
were implanted stereotaxically (O.S mm caudal, 4.S mm ventral, and 1.4 mm 
lateral from bregma) and then anchored onto 4 jewelers screws with dental 
cement and secured with stylets. Animals were allowed 2 weeks' recovery 
from surgery before the experiments. 
Catheters (PE SO tubing) were inserted under pentobarbital anesthesia 
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into the femoral artery and led subcutaneously to exit between the 
scapulae. Catheters were filled with a 50% sucrose solution containing 
1000 U/ml heparin. Arterial blood pressure recordings were made 24 hours 
after catheter implantation. 
Experimen~al Pro~ocols 
Initially, we wanted to determine the effective dose range for DOI to 
elevate renin secretion. Therefore, we injected increasing doses of DOI, 
from 0.05 mg/kg to 2.0 mg/kg, ip, 30 minutes before decapitation. This 
dose range was chosen due to the high selectivity reported for DOI 
(Shannon et al., 1984). 
Trunk blood of the decapitated rats was collected into centrifuge 
tubes containing 0.5 ml of a 0.3 M EDTA (pH 7.4) solution. The blood was 
centrifuged at 1000 x g for 25 minutes at 4°C and stored at -40°C until 
hormone determinations were completed. 
To determine receptor subtypes mediating the effects of DOI, two 
experiments were performed. In the first experiment, the 5-HT1c/5-HT2 
antagonist ritanserin was administered to conscious rats in doses of 
either 0 (vehicle), 0.01 or 0.1 mg/kg sc. Ritanserin was dissolved in 95% 
ethanol, then diluted with saline resulting in a final 10% ethanol-saline 
solution. The vehicle used was the same 10% ethanol-saline solution. 
Ritanserin has an extensive half life of greater than 2 hours (Van Nueten 
et al., 1986). The greater the time interval between drug injections, the 
less likely stress effects will occur. Therefore, the ritanserin 
injection was performed 1 hour prior to DOI administration. Rats were 
killed by decapitation 30 minutes following injection of DOI (ip). The 
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doses of DOI were based on the results from our initial dose-response 
experiment (fig. 3.1). These doses were: 0 (saline), 0.5, 1.0 or 10.0 
mg/kg. The highest dose of DOI was increased to 10. 0 mg/kg with the 
expectation of overcoming the effect of the antagonist. 
For the second experiment, spiperone was dissolved in 95% ethanol, 
then diluted with saline to a 10% ethanol-saline solution. The vehicle 
was also a 10% ethanol-saline solution for this experiment. Spiperone was 
injected in doses of 0 (vehicle), 0.01 or 0.1 mg/kg sc, 30 minutes before 
DOI administration (0, 1.0, 10.0 mg/kg, ip). The reported ED50 for 
spiperone blockade of quipazine-induced corticosterone secretion is 1.3 
mg/kg (Fuller, 1990). In addition, the doses we used were well below 
those reported to inhibit ACTH, corticosterone and ~-endorphin (Koenig et 
al., 1987; King et al., 1989). A 30 minute interval between spiperone and 
DOI injection was chosen because, unlike ritanserin, no information was 
available as to the duration of occupancy of 5-HT2 receptors in vivo. Rats 
were sacrificed 30 minutes after DOI injection. 
To investigate the location of the receptors mediating the effects of 
DOI, three experiments were performed. Initially, we administered the 
peripherally acting 5-HT2 antagonist xylamidine, 0.1 mg/kg ip, 30 minutes 
before DOI (0, 0.5, 1.0, 10.0 mg/kg ip). Rats were decapitated and trunk 
blood collected 30 minutes after injection of DOI. 
!CV injection of DOI. DOI was injected in doses below those 
peripherally effective (0, 1, 10, 100, 200 µg/kg) into the lateral 
cerebral ventricles via chronic, indwelling cannulae, in a volume of 20 
µl/kg. To determine the receptor specificity of DOI, rats were pretreated 
with vehicle (10% ethanol-saline) or 2.0 µg/kg ritanserin, 5 minutes prior 
to DOI injection. 
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The volume was also 20 µl/kg. Rats were killed 15 
minutes after DOI injection. 
For the third experiment, 0, 10, or 200 µg/kg of DOI were injected 
while recording arterial pressure changes for 30 minutes. Drugs were 
injected either ia or !CV. Blood samples (0.4 ml) were collected into 
tubes containing 50 µl EDTA, before and 5, 15, and 30 minutes after 
injection of DOI. Since 1.0 ml is necessary for the PRA assay, the plasma 
volume of 0.4 ml was not sufficient to assay both PRA and PRC. Therefore, 
only PRC was determined in these samples. 
Radioimmunoassays (RIAs) 
Plasma renin activity. Plasma renin activity was measured by RIA for 
generated angiotensin I (ANG I), as previously described (Richardson 
Morton et al., 1989). Briefly, 1.0 ml plasma samples were incubated for 
3 hours at 37°C to generate ANG I. The antiserum against ANG I was used 
at a dilution of 1:16,000 with total binding of 35%. The sensitivity 
limit of the RIA is 10 pg ANG I per tube. Intra-assay variability is 
4.4%, with inter-assay variability 12.6%. (Richardson Morton et al., 
1989). 
Plasma renin concentration. Plasma renin concentration was determined 
by addition of a saturating concentration of exogenous renin substrate 
(0.1 ml of plasma from nephrectomized, dexamethasone injected rats) to 50 
µl plasma samples and incubating at 37°C for 1 hour. The RIA of ANG I was 
the same as described above for plasma renin activity. 
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statistics 
Eight rats per group were used in all experiments unless otherwise 
stated in figure legends. RIA data were analyzed using RIA_AID software 
(Robert Maciel Associates, Arlington, MA). Statistical analysis of the 
data was performed using computer software (STATPAC, NWA, Portland, OR) by 
a 1-way or 2-way analysis of variance (ANOVA). Differences between the 
group means were analyzed by Newman Keuls' multiple range test (Steel and 
Torrie, 1960). 
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RESULTS 
'When injected ip into conscious male rats, DOI significantly [1-way 
ANOVA Fc 5 , 31 >-15.35, p<0.001] elevated both plasma renin activity and 
concentration (fig. 3.1). Plasma renin activity was increased eight-fold 
by the 2.0 mg/kg dose of DOI. The values for plasma renin activity and 
concentration resulting from the 2.0 mg dose of DOI (25 and 45 ng ANG I) 
are well above our previously reported maximal response to other 5-HT 
agonists (Van de Kar et al., 1989), demonstrating the high potency of DOI. 
Recep~or sub~ype 
In order to evaluate the specific 5-HT receptor mediating the effect 
of DOI on renin secretion, rats were pretreated with different 5-HT 
antagonists prior to increasing doses of DOI. When injected ip into 
conscious male rats, DOI again significantly [Fc3 , 84 >-19.47, p<0.0001] 
elevated both plasma renin activity and concentration (fig. 3.2). The PRC 
response to the 10 mg/kg dose of DOI was significantly greater than the 
1.0 mg/kg dose of DOI. The highest DOI dose (10 mg/kg) caused the same 
eight-fold increase in plasma renin activity and concentration as was seen 
with 2 mg/kg in our initial study (fig. 3.1), suggesting that a response 
plateau was reached by 2.0 mg/kg. Both the high (0.1 mg/kg) and the low 
dose (0.01 mg/kg) of ritanserin completely blocked the effect of all doses 
of DOI (fig. 3.2). The two-way ANOVA revealed a significant interaction 
between DOI and ritanserin [Fc 6 , 84 >-16.56, p<0.0001]. The post-hoc Newman 
Keuls' test showed that saline pretreated rats injected with 10.0 mg/kg 
DOI had significantly higher plasma renin values whether compared to their 
own controls or any of the ritanserin treated rats (p<0.01). 
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To differentiate between 5-HT1c and 5-HT2 receptor subtypes involved, 
we pretreated rats with spiperone, which has a higher affinity for 5-HT2 
receptors than 5-HT1c receptors (Hoyer, 1988). As shown in figure 3.3, 
after injection of spiperone, both plasma renin activity and plasma renin 
concentration exhibited a shift to the right in the dose-response curve 
for DOI, with a significant suppression of the maximal response. The 2-
way ANOVA showed a significant interaction between the effects of DOI and 
spiperone on renin activity [Fc 4 , 63 ,=6. 38, p<O. 0001). Newman-Keuls' test 
revealed that the group with the high dose of DOI (10. 0 mg/kg) was 
significantly greater than vehicle control as well as the corresponding 
10.0 mg/kg DOI groups treated with spiperone (p<0.01). None of the groups 
treated with spiperone were different from each other. It is important 
that a low dose of spiperone (0.01 mg/kg) was effective, suggesting that 
5-HT2 rather than 5-HT1c receptors mediate the effect of DOI. 
Loca~ion of recep~ors 
To distinguish central from peripheral 5-HT receptors mediating the 
renin response to ip administered DOI, we first injected the peripherally 
acting 5-HT1c/5-HT2 antagonist xylamidine. DOI dose-dependently increased 
plasma renin activity and concentration [Fc 3 , 51)=15.3, p<0.0001]. Figure 
3.4 shows that the DOI dose response curve was shifted to the right in the 
xylamidine pretreated rats. A two-way ANOVA indicated that the 
interaction between DOI and xylamidine approached, but did not achieve 
statistical significance [Fc 3 , 51 ,=2. 3, p>O. 08]. However, a post-hoc Newman 
Keuls' test revealed that there was a significant reduction in renin 
activity and concentration in rats injected with 10 mg/kg DOI and 
pretreated with xylamidine, compared to those pretreated with saline 
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(p<0.01), suggesting a decrease in the maximal response. The PRA response 
to the 1.0 mg/kg dose of DOI was significantly higher than the 
corresponding group treated with xylamidine (p<0.01). These data suggest 
a role for peripheral 5-HT2 receptors in the renin response to DOI. 
To investigate the central effects of DOI directly, we injected low 
doses of DOI into the lateral cerebral ventricles. The plasma renin 
concentration data demonstrate a dose-response effect due to DOI more 
clearly than the plasma renin activity data (fig. 3.5), although both were 
affected [PRA: Fc 4 , 55 >=19.4, p<0.0001; PRC: Fc 4 , 55 >=19.24, p<0.0001]. Only 
the 200 µg/kg dose of DOI significantly elevated plasma renin activity and 
concentration compared to the saline controls (Newman Keuls' test, 
p<0.01). ICV injected ritanserin (2 µg/kg) did not significantly affect 
the renin response to ICV administered DOI. 
DOI has impressive cardiovascular effects, whether administered ICV or 
ia. Representative arterial pressure tracings for vehicle (A), 200 µg/kg 
DOI-ia (B), and 200 µg/kg DOI-ICV (C) are shown in figure 3.6. Note also 
the larger increase in pulse pressure following ICV DOI injection (fig. 
3.6C). Figure 3.7 shows the complete data for all the groups. We found 
that DOI, injected ICV at 10, and 200 µg/kg produced a maximal elevation 
in BP of 10 ± 1.5 and 40 ± 3.6 mm Hg respectively, within 10 minutes post-
injection (fig. 3. 7, middle panel). In contrast, ia injection of 200 
µg/kg DOI caused a more delayed rise (15 minutes post-injection) in BP as 
well as a lower maximal response of 28 ± 3.2 mm Hg (fig. 3.7, middle 
panel). Both ICV and ia administration of 200 µg/kg DOI caused 
significant blood pressure elevations at all time points compared to 
saline controls (Newman Keuls' test p<O. 01). However, blood pressure 
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increases after rev injections were significantly higher at 5 (p<0.05) and 
10 minutes (p<0.01) than the corresponding values for ia injection. The 
renin data accompanying these changes in blood pressure are also 
summarized in figure 3. 7 (top panel). At 5 minutes, plasma renin 
concentration was significantly increased in rats receiving 200 µg/kg DOI-
rev, compared to rats receiving vehicle control or DOI- ia injections 
(Newman Keuls' test, p<0.01). At 15 minutes, rats injected IeV still had 
elevated renin secretion (p<O. 01) whereas rats injected ia had just 
attained a significant increase in plasma renin concentration (p<0.05), 
compared to saline controls, at the same time point. DOI-rev 200 µg/kg 
caused a reduction in heart rate (p<0.05), whereas DOI-ia 200 µg/kg did 
not cause any change (fig. 3.7, bottom panel). There were no significant 
changes after rev injection of 10 µg/kg DOI in any of the parameters 
measured. 
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Figure 3.1. The effect of increasing doses of DOI on plasma renin 
activity and concentration. DOI was administered ip. The data represent 
the mean± S.E.M. of eight rats per group. **Significant difference from 
the corresponding control (saline) group, P<0.01 (one-way ANOVA and Newman 
Keuls' test). 
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Figure 3.2. The effect of increasing doses of DOI on plasma renin 
activity and concentration in rats pretreated with either 0.01 or 0.1 
mg/kg ritanserin. DOI was administered ip, ritanserin sc. The data 
represent the mean ± S. E .M. of eight rats per group. ** Significant 
difference from the corresponding control (saline) group, P<0.01 (two-way 
ANOVA and Newman Keuls' test). 
~ 
> 
I-(..) 
< 
z 
z 
w 
0:::: 
< 
::E 
(/) 
:5 
a.. 
z 
0 
80 
....:-
.s:. 60 ,,, 
........ 
E 
........ 
(; 40 
~ 
0 
c 
- 20 
180 
~ 150 ~ -.:-
w .s:. 
u ~120 8s 
z ~ 90 
z ~ 
~ s 60 
< 
0 
o-o SALINE PRETREATED 
•- • SPIPERONE 0.01 mg/kg 
6· · 6 SPIPERONE 0.1 mg/kg 
1.0 
DOSE OF DOI (mg/kg, ip) 
o-o SALINE PRETREATED 
•-e SPIPERONE 0.01 mg/kg 
6· · 6 SPIPERONE 0.1 mg/kg 
10.0 
** I 
J 
/~ t /.· 
/." 
......... 
:::E 
s JO --~ .. a. ~Q_.... .. a.. -=:....:... :-:.. :.....&.. ...-.-~··· • 
0 1.0 10.0 
DOSE OF DOI (mg/kg, ip) 
so 
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activity and concentration in rats pretreated with either 0. 01 or 0 .1 
mg/kg spiperone. DOI was administered ip, spiperone sc. The data 
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Figure 3. 4. The effect of DOI on plasma renin activity and 
concentration in rats pretreated with 0. 1 mg/kg xylamidine. DOI and 
xylamidine were injected ip. The data represent the mean± S.E.M. of six 
to eight rats per group. ** Significant difference from the corresponding 
control group, P<O. 01; ## significant difference from 10. 0 mg/kg DOI 
group, P<0.01 (two-way ANOVA and Newman Keuls' test). 
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Figure 3.5. The effect of !CV injected DOI on plasma renin activity 
and concentration in rats pretreated with !CV ritanserin. Ritanserin was 
dissolved in 2.5% ethanol, and injected at a dose of 2.0 µg/kg in 20µ1. 
The data represent the mean± S.E.M. of six to eight rats per group. * 
Significant difference from corresponding control group, P<0.05; ** 
significant difference from corresponding control group, P<0.01 (two-way 
ANOVA and Newman Keuls' test). 
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Figure 3.6. Arterial pressure tracings recorded from the femoral 
artery in freely moving rats. Panel A: Control, ICV injection of vehicle. 
Panel B: ia injection of 200 µg/kg DOI; injection was complete at time 0. 
Panel C: ICV injection of 200 µg/kg DOI; injection was complete at time O; 
DOI was injected at a rate of 1.0 µl/10 sec; injection volume was 20 
µl/kg. 
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Figure 3.7. Time course after DOI injection of vehicle, 200 µg/kg 
ICV, 10 µg/kg ICV, or 200 µg/kg ia. Top panel: PRC. Middle panel: change 
in BP. Bottom panel: change in HR; there was no change in HR after 
injection of DOI 10 µg/kg ICV. Therefore, it was omitted from the figure 
in the interest of clarity. For each panel, ** or * is significantly 
different from the corresponding ia group (P<O. 01 and P<O. 05 
respectively). The number of rats per group: top = 8; middle = 11; bottom 
= 8 (repeated measures, 2-way ANOVA). 
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DISCUSSION 
The data in this study suggest that DOI, a S-HT1c/S-HT2 agonist, 
stimulates renin secretion in part through activation of S-HT2 receptors. 
Furthermore, these data suggest that the DOI-induced increase in renin 
release is mediated by both central and peripheral sites of action. 
Therefore, DOI' s mechanism of action is probably more complex than 
previously thought. 
The ability of both ritanserin and spiperone to antagonize the effect 
of DOI on renin secretion at low doses (0.01-0.l mg/kg) suggests that S-HT2 
receptors, for which they both have a high affinity, were blocked. 
Evidence suggests that activation of S-HT1c receptors increases ACTH and 
corticosterone secretion (King et al., 1989). The antagonists ritanserin 
and spiperone have a high and approximately equal affinity for S-HT2 
receptors. Ritanserin also binds with the same affinity to S-HT1c 
receptors, while spiperone binds with an approximately 100-fold lower 
affinity to S-HT1c receptors (Hoyer, 1988). This difference in affinity 
is also manifested in vivo by the low potency (a high ED50 of l.S mg/kg) 
for spiperone' s ability to antagonize the effect of the S-HT agonist 
quipazine on corticosterone secretion (Fuller and Snoddy, 1990). The 
spiperone doses we used were well below those reported to inhibit ACTH, 
corticosterone and ~-endorphin responses to S-HT agonists (Koenig et al., 
1987; King et al., 1989). Doses of spiperone as high as 3 mg/kg did not 
inhibit the effect of the S-HT1c agonist MK-212 on ACTH secretion (Koenig 
et al., 1987; King et al., 1989). Therefore, the ability of spiperone to 
inhibit the DOI-induced increase in plasma renin at doses of 0. 01-0 .1 
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mg/kg suggest that it blocked 5-HT2 receptors. 
A comparison of the increases in plasma renin activity between figures 
3 .1 and 3. 2 indicates that the DOI doses of 2 and 10 mg/kg produced 
comparable changes in PRA and PRC, suggesting that a maximal plateau had 
been achieved. The dose of 10 mg/kg was used in an attempt to surmount 
the antagonist effects of ritanserin, spiperone and xylamidine. The 
inability of the high dose of DOI to overcome the antagonist effect of 
ritanserin suggests that it might be noncompetitive or irreversible. 
Leysen et al. (1985) observed that the inhibition of [3H]ketanserin binding 
by ritanserin was noncompetitive. Our data also indicate that ritanserin 
may inhibit the DOI-induced increase in renin secretion in a 
noncompetitive manner. If the inhibition were competitive in nature, the 
maximal response achieved at the highest dose of DOI would have been 
decreased, but not completely suppressed, in the presence of the 
antagonists. However we observed a significant reduction of the maximal 
response at the high dose of DOI in the presence of ritanserin. Thus, we 
conclude that ritanserin may be functioning in a noncompetitive manner, 
presumably via 5-HT2 or 5-HT1c receptors. 
Binding experiments indicated that a ritanserin dose of 0 .1 mg/kg 
occupies 50% of brain 5-HT2 receptors (Leysen et al., 1985). Surprisingly, 
even our low dose of 0.01 mg/kg ritanserin completely blocked the renin 
response, suggesting the high selectivity of this antagonist for 5-HT2 
receptors. It should be noted that 5-HT2 receptors exist in high and low 
affinity states defined by their coupling to the G-protein. 3H-Ketanserin 
labels low affinity sites. The affinity of 5-HT agonists and antagonists 
for the 5-HT2 high affinity sites ( 125I-DOI binding sites) is higher than 
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their affinity for 3H-ketanserin sites. Furthermore, the Bmax of 1251-DOI 
for 5-HT2 (agonist) sites is at least 10-fold lower than the Bmax for 3H-
ketanserin sites (Teitler et al., 1990). Thus, it is conceivable that low 
doses of 5-HT2 antagonists would be effective in vivo in inhibiting the 
neuroendocrine effects of DOI. 
The combined evidence of the xylamidine and rev experiments suggests 
that DOI stimulates 5-HT2 receptors both centrally and peripherally. We 
chose to use the 5-HT1c/5-HT2 antagonist xylamidine because of its apparent 
inability to cross the blood brain barrier (Copp et al., 1967). 
Consequently, any inhibition of DOI' s stimulation of renin release by 
xylamidine, could be attributed to peripheral effects. We found that 
xylamidine caused a shift to the right in the renin dose-response curves, 
suggesting a role for peripheral 5-HT2 receptors. In addition, the 
inability of centrally administered ritanserin to inhibit the ICV DOI-
induced increase in renin secretion (fig. 3.5) suggests that DOI may be 
leaking to the periphery and acting there, or that it acts centrally on a 
different receptor. However, the dose-response effect of ICV injected 
DOI on plasma renin concentration suggests that DOI can mediate its 
effects via interacting with central 5-HT receptors. 
Alper (1990b) found that as little as 100 µg/kg DOI was needed to 
increase renin when injected intravenously. Alper concluded that DOI can 
stimulate renin secretion through a peripheral mechanism, specifically by 
reducing renal blood flow. Zink et al. (1990) demonstrated that quipazine 
also increased renin secretion through this same peripheral mechanism. 
Shoji et al. (1989) found that 5-HT1 and 5-HT2 receptors in the renal 
vasculature were responsible for the decrease in renal blood flow 
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following intrarenal serotonin infusion. Hence, DOI could increase renin 
release by acting in the renal arterioles. Vayssettes-Courchay et al. 
(1990b) showed that the pressor response after iv injection of quipazine 
is mediated by peripheral vascular and myocardial 5-HT2 receptors. 
However, our data suggest 5-HT mediated changes in renin responses 
involve, in part, a central mechanism. The ICV responses to DOI, 
increased blood pressure and renin concentration with decreased heart 
rate, were all significantly higher than ia injection of the same dose of 
DOI (fig. 3.7). Thus, these data suggest a site of action for DOI 
localized within the brain. 
Other evidence exists which would suggest a central site of action for 
DOI to stimulate renin secretion. Porter (1988) found that electrical 
stimulation of the paraventricular nucleus of the hypothalamus (PVN) 
caused an increase in plasma renin activity with no change in blood 
pressure. Richardson-Morton et al. (1989) demonstrated that cell bodies 
in the PVN mediate stress-induced elevations in renin secretion. Appel et 
al. (1990) found higher [1251]-DOI binding in the PVN than other 
hypothalamic nuclei. Gotoh et al. (1987; 1988) reported that lesions in 
either the PVN or the ventromedial nucleus of the hypothalamus (VMN) 
inhibit the plasma renin activity response to the 5-HT releaser p-
chloroamphetamine (PCA). Another 5-HT agonist, RU 24969, injected into 
the PVN also increased plasma renin activity and concentration (Van de Kar 
et al., 1990). 
An additional site of action for DOI could be in the circumventricular 
organs, such as the subfornical organ or the area postrema. These organs, 
which lie outside the blood brain barrier, are highly vascularized and 
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have connections to cardiovascular and autonomic control centers in the 
brain (Miselis, 1981; Shapiro and Miselis, 1985). Thus, they may be a 
bridge connecting "peripheral" receptor sites with central renin 
regulatory sites. Immunoreactive 5-HT cell bodies in the area postrema 
(Lind, 1986) and fibers in the area postrema and subfornical organ (Newton 
et al., 1985) have been reported. 5-HT3 receptors have been identified in 
the area postrema using autoradiography (Radja et al., 1991). 
Elevated blood pressure is an effective inhibitor for renin secretion 
through the renal "stretch" receptor (Tobian et al., 1959). Thus, if DOI 
were stimulating renin release exclusively through a cardiovascular 
mechanism, then elevated blood pressure should depress, not raise renin 
secretion as shown in figure 3. 7. Since no change in heart rate was 
reported by several investigators (Dabire et al., 1989; McCall and Harris, 
1988) following DOI administration it is likely that an increase in 
sympathetic nerve activity overrides the baroreceptor reflex response to 
increased blood pressure. Our data show that !CV injection of DOI 
potently decreases heart rate (fig. 3.7), while ia injection of DOI causes 
no change. These data also support a central site of action for DOI. 
Kushiro et al. (1988) have implicated central 5-HT2 receptors in blood 
pressure regulation, since rev ketanserin blocked the pressor response 
caused by !CV 5-HT injection. Several investigators have suggested that 
the ventral surface of the medulla may be the site of DOI' s pressor 
response (King and Holtman, 1990; Gillis et al., 1989). 
Our experiments showed that it did not matter which route of 
administration was used for DOI to increase blood pressure. Either ia or 
ICV, DOI was a vigorous pressor agent. However, ICV injection clearly 
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resulted in a more robust response of each parameter measured: renin, BP 
or HR (fig. 3. 7). In addition, the large expansion in pulse pressure 
(fig. 3.6) following ICV injection of DOI suggests that elevated 
sympathetic outflow is causing a direct increase in cardiac contractility. 
Therefore, distinct receptor subtypes may be activated on either side of 
the blood brain barrier. As mentioned above, the circumventricular 
organs, renal vasculature, or myocardium are possible peripheral sites of 
action, while sites within the brain include the paraventricular or 
ventromedial nuclei of the hypothalamus and/or the ventrolateral medulla. 
In conclusion, our data indicate that DOI stimulates renin secretion 
through 5-HT2 receptors. Our data indicate that both central and 
peripheral components are involved in DOI's stimulation of renin secretion 
and blood pressure. 
CHAPTER IV 
EVIDENCE THAT RU 24969 AND P-CHLOROAMPHETAMINE STIMULATE RENIN 
SECRETION THROUGH CENTRAL SEROTONERGIC MECHANISMS 
INTRODUCTION 
The control of renin secretion may have both central and peripheral 
sites of regulation. Peripherally administered serotonin (5-HT) agonists 
and releasers reliably elevate plasma levels of renin (Van de Kar, 1991). 
Other evidence suggests that the 5-HT receptors regulating this endocrine 
function are located in the brain (Van de Kar et al., 1981; Karteszi et 
al., 1982; Van de Kar et al., 1989). Previous investigations have shown 
that the serotonin agonist DOI stimulates renin release through activation 
of both central and peripheral 5-HT2 receptors (Rittenhouse et al., 1991; 
Alper, 1990a). The aim of the present study was to determine if the 5-HT 
agonist RU 24969 and the 5-HT releaser p-chloroamphetamine (PCA) act in 
the brain to stimulate renin release from the kidney. 
RU 24969 is an indole derivative considered to be a mixed 5-HT1,J5-HT1B 
agonist (Glennon, 1987). However, the effect of RU 24969 on renin 
secretion has been blocked by the 5-HT1c/5-HT2 antagonist ritanserin, and 
therefore RU 24969 is thought to increase renin secretion through 
activation of 5-HT1c/5-HT2 receptors (Van de Kar et al., 1989). Increasing 
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doses of RU 24969 have not been administered directly into the brain. 
Intravenous administration of RU 24969 causes a dose dependent decrease in 
blood pressure (Cherqui et al., 1988), suggesting cardiovascular factors 
may contribute to the renin response. 
The mechanism by which PCA stimulates renin secretion remains subject 
to debate. When injected peripherally (ip), PCA causes a dose-dependent 
increase in renin secretion (Van de Kar et al. , 1981). Intravenous 
administration of PCA does not increase renin secretion unless preceded by 
the a 1 antagonist prazosin (Alper et al., 1990). PCA releases both 5-HT 
and catecholamines from nerve terminals (Sanders-Bush and Steranka, 1978; 
Sharp et al., 1986). Evidence suggests that the increase in renin caused 
by PCA is mediated by either 5-HT from the dorsal raphe (Van de Kar et 
al., 1981) or the sympathetic nervous system (Alper and Ganong, 1984). 
PCA has also been shown to increase blood pressure when administered 
peripherally (Alper et al., 1987). However, recent reports suggest that 
renal toxicity may be responsible for increased renin secretion subsequent 
to peripherally injected PCA (Ikonomov et al., 1991). Thus, we decided to 
explore more thoroughly the mechanism underlying PCA's ability to elevate 
plasma renin levels. 
In the present studies, we injected either RU 24969 or PCA into the 
lateral cerebral ventricle (ICV), using doses below those peripherally 
effective (Van de Kar et al., 1981; Van de Kar et al., 1989). The 5-
HT1c/5-HT2 antagonist LY53857 was used to verify the 5-HT receptor subtype 
influencing renin secretion (Hoyer and Schoeffter, 1991). In separate 
experiments, blood pressure and heart rate were measured, subsequent to 
ICV drug administration. Additional control experiments were performed 
63 
with fluoxetine, a 5-HT uptake inhibitor (Fuller et al., 1991), and 
prazosin, an a 1 antagonist (Cavero and Roach, 1980) to investigate PCA's 
mechanism of action. The purpose of these experiments was to determine if 
5-HT receptors in the brain mediate the renin response to RU 24969 and PCA 
in conscious male rats, or whether other mechanisms are involved. 
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METHODS 
Animals 
Male Sprague-Dawley rats (275-300g) were purchased from Sasco-King 
Animal Laboratories. The rats were housed 2 per cage in a climate and 
illumination (12:12 hr light/dark cycle, lights on at 7:00 AM) controlled 
room. Water and rat chow (Wayne Lab Blox, Lab Mills Inc., Chicago, IL) 
were available ad libitum. Experiments were conducted between 11:00 A.M. 
and 3 :00 P .M. All protocols were approved by the Loyola University 
Institutional Animal Care and Use Committee, and were conducted in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals. 
Surgery 
Implantation of !CV cannulae and intra-femoral catheters were 
performed under pentobarbital anesthesia (50 mg/kg, ip). Animals were 
pretreated with ampicillin (50 mg/kg, sc) to prevent infection and 
atropine (0.2 mg/kg, ip) to reduce excessive secretions. 
The !CV guide cannulae (33 gauge, Plastics One, Roanoke, VA) were 
implanted stereotaxically using the coordinates: 0.5 mm caudal, 4.6 mm 
ventral, and 1.4 mm lateral from bregma (Paxinos and Watson, 1986). The 
cannulae were anchored onto 4 jewelers screws with dental cement, and 
secured with stylets. Animals were allowed 2 weeks recovery from surgery 
before the experiments. For each experiment, cannulae placement was 
verified after decapitation by injection of fast green dye through the 
cannulae into the ventricle. Rats having improperly placed cannulae were 
not used in the data analysis. 
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Catheters (PE 50 tubing) were inserted into the femoral artery and led 
subcutaneously to exit between the scapulae. Catheters were filled with 
a 50% sucrose solution containing 1000 u/ml heparin. Arterial blood 
pressure recordings were made 24 hours following catheter implantation on 
a Grass polygraph. 
Experimental Protocols 
Experiment 1. To investigate whether a 5-HT antagonist injected 
into the brain could inhibit a peripherally administered 5-HT agonist, !CV 
cannulae were implanted stereotaxically into male rats. Following 2 weeks 
recovery from surgery, the 5-HT1c/5-HT2 antagonist LY53857 (50 µg/kg) was 
injected !CV into conscious rats. Fifteen minutes later, RU 24969 was 
injected ip (0, 1.0, 5.0, 10.0 mg/kg). Rats were decapitated 30 minutes 
after the RU 24969 injection, and their trunk blood collected into chilled 
tubes containing 0. 5 ml EDTA. 
determination of renin. 
Plasma was stored at -40° C until 
Experiment 2. This experiment was designed to determine if RU 24969 
had a direct action in the brain to elevate plasma renin levels. !CV 
cannulae were implanted as described above. On the day of the experiment, 
LYS3857 (10 µg/kg) was injected !CV into conscious rats. Fifteen minutes 
later, RU 24969 was also injected !CV (0, 10, 100, 200 µg/kg). Rats were 
decapitated 30 minutes later, and their trunk blood collected into chilled 
tubes containing 0. 5 ml EDTA. 
determination of renin. 
Plasma was stored at -40° C until 
Experiment 3. This control experiment was performed to determine if 
cardiovascular factors influence RU 24969's ability to stimulate renin 
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secretion. !CV cannulae were implanted. Two weeks later, catheters were 
inserted into the femoral artery under pentobarbital anesthesia. Twenty-
four hours later blood pressure (BP) and heart rate (HR) were recorded. 
RU 24969 (200 µg/kg) was administered either centrally through the !CV 
cannulae or peripherally through the femoral artery. BP and HR were 
recorded for 30 minutes after drug injection. 
Experiment 4. Fluoxetine is a 5-HT uptake inhibitor (Fuller et al., 
1991). To verify that PCA is stimulating renin secretion through a 
serotonergic mechanism and not another transmitter, this control 
experiment was performed. Fluoxetine was administered 3 hours prior to 
sacrifice (10 mg/kg, ip). PCA was administered 1 hour prior to sacrifice 
(8 mg/kg, ip). These time periods were chosen due to the extended 
duration of action of each drug (Fuller et al., 1975). 
collected and stored at -40° until renin determination. 
Plasma was 
Experiment 5. This experiment was designed to determine if PCA had a 
direct action in the brain to elevate plasma renin levels. After the 2 
week recovery period following !CV surgery, LY53857 (20 µg/kg) was 
injected !CV into conscious rats. Fifteen minutes later, PCA was also 
injected !CV (0, 50, 500, 1000 µg/kg). Rats were decapitated 1 hour 
later, and their trunk blood collected into chilled tubes containing 0.5 
ml EDTA. Plasma was stored at -40° C until determination of renin. 
Experiment 6. Results from experiment 5 suggested that 
cardiovascular parameters could be influencing the renin response to PCA, 
which prompted the following experiment. !CV cannulae were implanted as 
described above. Two weeks later, catheters were inserted into the 
femoral artery under pentobarbital anesthesia. Twenty-four hours later 
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blood pressure (BP) and heart rate (HR) were recorded. PCA (1000 µg/kg) 
was administered either centrally through the ICV cannulae or peripherally 
into the femoral artery. BP and HR were recorded for 1 hour following 
drug injection. The vehicle (saline) injected controls were measured for 
only 30 minutes. 
Experiment 7. An additional experiment was performed to control for 
PCA's vasoconstrictive actions. ICV cannulae were implanted 
stereotaxically. After 2 weeks recovery, the o1 antagonist prazosin was 
injected (1.0 mg/kg, sc). Fifteen minutes later, PCA was injected ICV 
(500 µg/kg) into conscious rats. Rats were decapitated 1 hour later, 
their trunk blood saved for renin determination, and cannulae placement 
verified with fast green dye. 
Drugs 
PCA and prazosin were purchased from Sigma Chemical Co. (St. Louis, 
MO). RU 24969 was donated by Roussel Uclaf (Romainville, France). 
LY53857 and fluoxetine were donated by Eli Lilly & Company (Indianapolis, 
IN). Prazosin was dissolved in ethanol then adjusted with distilled H20 
to a 10% ethanol in distilled H20 solution. The other drugs were dissolved 
in a 0. 9% saline solution. ICV injected drugs were in a volume of 20 
µl/kg, while ip injected drugs were in a volume of 1.0 ml/kg. 
Radioimmunoassays (RIA's) 
Plasma renin activity. Plasma renin activity (PRA) was measured by 
RIA for generated ANG I, as previously described (Richardson Morton et 
al., 1989). Briefly, 1.0 ml plasma samples were incubated for 3 hours at 
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37oc to generate ANG I. The antiserum against ANG I was used at a dilution 
of 1:16,000 with total binding of 30%. The sensitivity limit of the RIA 
is 10 pg ANG I per tube. Intra-assay variability was 4.4%, with inter-
assay variability 12. 6%. (Richardson Morton et al., 1989). PRA is a 
reflection of the ability of the native enzyme renin in a given plasma 
sample to generate ANG I from endogenous substrate (angiotensinogen). It 
is therefore substrate dependent. 
Plasma renin concentration. Plasma renin concentration (PRC) was 
determined by addition of exogenous renin substrate (0 .1 ml of plasma from 
nephrectomized, dexamethasone injected rats) to 50 µl plasma samples and 
incubating at 37°C for 1 hour. The RIA of ANG I was the same as described 
above for plasma renin activity. PRC represents the maximal response 
possible since a saturating concentration of renin substrate is added to 
each plasma sample, and thus is substrate independent. 
Statistics 
Eight rats per group were used in all experiments unless otherwise 
stated in figure legends. RIA data were analyzed using RIA_AID software 
(Robert Maciel Associates, Arlington, MA). Statistical analysis of the 
data was performed using computer software (STATPAC, NWA, Portland, OR) by 
either a 2-way analysis of variance (ANOVA) or 1-way ANOVA with repeated 
measures. The group means were compared by Newman Keuls' multiple range 
test (Steel and Torrie, 1960). 
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RESULTS 
RIJ 24969 
our first experiment was designed to determine if a centrally 
administered antagonist could block the effect of a peripherally injected 
agonist. Figure 4.1 shows a shift to the right and a reduction in the 
renin maximal response to RU 24969 in rats pretreated with the 5-HT1c/5-HT2 
antagonist LY53857 (ICV). RU 24969 caused a significant elevation of both 
PRA (Fc 3 , 60 >-8 .13, P<O. 0001) and PRC (Fc 3 , 60 >=13. 23, P<O .0001). In animals 
pretreated with LY53857, there was a significant decrease in the renin 
response to RU 24969 (PRA: Fc 1 ,so>=8. 97, P<O. 005; PRC: Fc 1 , 60 >-17. 97, 
P<0.0001). Although there was not a significant interaction between 
LY53857 and RU 24969 on the PRA response, post-hoc analysis revealed that 
at the highest dose of RU 24969, there was a significant decrease in PRA 
caused by LY53857 (P<0.05). LY53857 produced a significant reduction in 
the PRC response to RU 24969 (interaction Fc 3 , 60 >=2.21, P<0.05). 
In figure 4.2, RU 24969 administered centrally (ICV, 10-200 µg/kg) 
elevated plasma renin in a dose-dependent manner (PRA, Fc 3 , 64 >-15. 0, 
P<0.0001; PRC, Fc 3 , 64 >=11.84, P<0.0001). Post-hoc Newman Keuls' analysis 
showed that the 100 and 200 µg/kg doses of RU 24969 significantly 
increased PRA compared to saline pretreated rats (P<O. 05 and P<O. 01 
respectively). In LY53857 pretreated rats, only the highest dose of RU 
24969 produced an effect significantly above saline (P<0.01). PRC was 
significantly elevated at the highest dose of RU 24969 regardless of 
LY53857 treatment. 
To determine cardiovascular mechanisms, mean arterial blood pressure 
was measured (fig. 4.3). !CV injections of RU 24969 caused a significant 
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elevation (P<0.05) in blood pressure at 5 minutes-post injection, compared 
to blood pressures at time 0 or 30 minutes post-injection. The same dose 
injected ia did not cause a significant elevation in mean blood pressure. 
By 30 minutes, the time at which blood was collected for the previous two 
experiments, blood pressure had normalized. There were no significant 
changes in heart rate between any of the groups during the 30 minute 
recording session. However, there was a reduction in heart rate following 
rev administration of RU 24969, which mirrored the rev BP elevation. 
P-chloroamphetamine 
Our working hypothesis is that PCA elevates plasma renin levels 
through a serotonergic mechanism. To confirm this, the ability of 
fluoxetine to inhibit the renin elevating effect of PCA was tested. As 
shown in figure 4. 4, ip administration of PCA caused a significant 
increase in both PRA and PRC, compared to saline treated controls (Newman 
Keuls' test P<0.01). Pretreatment with the 5-HT uptake inhibitor 
fluoxetine blocked the PRA (interaction, Fc 1 , 26 >-10. 07, P<O. 005) and PRC 
(interaction, F c1 •26 >=21. 87, P<O. 0001) response to PCA. Fluoxetine alone 
had no significant effect on renin secretion. 
PCA was injected into the lateral cerebral ventricle (rCV), using 
doses below those peripherally effective. There was no significant change 
in either PRA or PRC at any dose of PCA (fig. 4.5). LY53857 had no effect 
on the renin response to PCA. 
To determine if cardiovascular mechanisms were blunting the renin 
response, blood pressure and heart rate were measured following rev 
injection of PCA. PCA caused a significant increase in blood pressure 
after rev administration (Fc 5 , 48 >=11.85, P<0.0001). As shown in the top 
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panel of figure 4.6, there was a rapid and robust blood pressure elevation 
at 2 and 5 minutes (Newman Keuls' P<O. 01). The maximal response was 
approximately 45 mm Hg above the baseline vehicle injected controls. When 
administered peripherally into the femoral artery the same dose of PCA 
elevated blood pressure only 10 mm Hg at 5 minutes. The lower panel of 
figure 4.6 shows changes in heart rate after PCA administration. When 
injected !CV, there was a rapid but non-significant increase in heart rate 
which paralleled the blood pressure response seen in the upper panel. 
Following this initial tachycardia, heart rate slowed at 15 minutes, then 
increased again by 60 minutes (Newman Keuls' test P<0.05, compared to 15 
minutes). Vehicle (saline) injected !CV caused no changes in either blood 
pressure or heart rate. 
To determine if vasoconstriction due to PCA was masking a stimulatory 
effect on renin secretion, the a 1 antagonist prazosin was administered (sc) 
prior to PCA injection (!CV). As shown in figure 4.7, PCA again produced 
a non-significant reduction in both PRA and PRC when administered alone 
into the brain ventricles. Prazosin alone caused a significant elevation 
(320%) in plasma renin activity compared to vehicle/saline controls 
(P<0.05). An increase was also observed in PRC (230%), although this did 
not reach statistical significance. The combination of prazosin 
pretreatment plus PCA caused an additional significant (P<0.01) increase 
(greater than 315% for both PRA and PRC) in the renin response above 
prazosin alone (PRA interaction, Fc 1 , 32 ,-9. 86, P<O. 005; PRC interaction, 
FCl, 33 ,-11. 02, P<O. 005). 
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Figure 4.1. Effect of peripherally administered RU 24969 on plasma 
renin activity (top) and concentration (bottom) in rats pretreated with 
LYS3857 (ICV). Data represent mean± S.E.M. of 8 rats per group. ** 
Significant difference from corresponding saline (0 dose of RU 24969) 
group, P<O. 01; # or ## significant difference from corresponding RU 
24969-saline pretreated group, P<0.05 or P<0.01 respectively (2-way ANOVA 
and Newman Keuls' test). 
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Figure 4.2. Effect of ICV administered RU 24969 on plasma renin 
activity (top) and concentration (bottom) in rats pretreated with LY53857 
(ICV). Data represent mean± S.E.M. of 8 rats per group. * or ** 
Significant difference from corresponding saline group, P<0.05 or P<0.01 
respectively (2-way ANOVA and Newman Keuls' test). 
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Figure 4.3. Cardiovascular effects of RU 24969 following central or 
peripheral administration. RU 24969 was injected either ICV or ia at time 
0 to conscious male rats. Data represent mean ± S.E.M. of 8 rats per 
group. * Significant difference from corresponding vehicle (saline) 
group, P<0.05 (1-way ANOVA, repeated measures and Newman Keuls' test). 
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Figure 4.5. Effect of centrally administered PCA on plasma renin 
activity (top) and concentration (bottom). Data represent mean± S.E.M. 
of 8 rats per group. 
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Figure 4. 6. Cardiovascular effects of PCA fol lowing central or 
peripheral administration. PCA was injected either ICV or ia at time 0 to 
conscious male rats. Data represent mean± S.E.M. of 8 rats per vehicle 
(saline) group, 4 rats per PCA-ia group, and 9 rats per PCA-ICV group. * 
or ** Significant difference from corresponding vehicle group, P<0.05 or 
P<O. 01 respectively (1-way ANOVA, repeated measures and Newman Keuls' 
test). 
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DISCUSSION 
Evidence from this investigation indicates that brain serotonin 
pathways can stimulate renin release from the kidney. The results show 
that the S-HT agonist RU 24969 increased renin secretion through 
activation of S-HT receptors located in the brain. The results also 
demonstrate that the S-HT releaser PCA acting centrally, can stimulate 
renin secretion, if its vasoconstrictive effects are inhibited with an a 1 
antagonist. 
The focus of this study was to investigate whether S-HT in the brain 
is an important regulator of renin secretion. RU 24969 and PCA were used 
as tools to test this hypothesis. Both of these drugs are known to 
elevate plasma renin levels if injected peripherally (Van de Kar, 1991). 
RU 24969 
Central administration of the S-HT1c/S-HT2 antagonist LYS38S7 produced 
a clear shift to the right in the renin dose-response curve, as well as a 
reduction in the maximum effect of ip injected RU 24969. These data 
suggest that RU 24969 injected peripherally stimulates renin secretion 
through S-HT2 receptors located in the brain. The possibility exists that 
at SO µg/kg, LYS38S7 could have "leaked" out of the brain to antagonize 
peripheral S-HT2 receptors. However, in a previous study (Van de Kar et 
al., 1989) a dose of 1.0 mg/kg LYS38S7 (ip) inhibited, but did not 
completely block, the effect of RU 24969 on renin secretion. Since this 
dose was 20 times higher and injected peripherally, it seems unlikely that 
our dose of SO µg/kg LYS38S7 injected ICV would be large enough to reach 
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peripheral targets. 
When RU 24969 was injected directly into the brain ventricles, using 
doses below those which are peripherally effective, there was a dose-
related increase in renin secretion (both PRA and PRC). These data also 
demonstrate that centrally located 5-HT receptors are mediating the renin 
response. A low dose of LY53857 was used to maintain receptor subtype 
selectivity. While there was a "suggestion" of a shift in the curve to 
the right, the antagonist dose used might not have been high enough. 
The rationale for using a 5-HT2 antagonist (LY53857) to inhibit the 
renin response to a 5-HT1A/5-HT1B agonist (RU 24969) was based on two lines 
of evidence. First, previous studies have verified that renin is 
stimulated by activation of 5-HT2 receptors (Bagdy et al., 1992; 
Rittenhouse et al., 1991; Alper, 1990a). Secondly, Van de Kar et al. 
(1989) were able to inhibit the renin response to peripherally 
administered RU 24969 with two different 5-HT2 antagonists, namely LY53857 
and ritanserin. The explanation as to why the effect of RU 24969 can be 
blocked by 5-HT2 antagonists was provided by Lyon et al. (1987) who showed 
that RU 24969 binds with 20 times higher affinity to the 5-HT2 high 
affinity site (Ki=42nM; labeled with 3H-DOB) compared to the 5-HT2 low 
affinity site (Ki=777nM; labeled with 3H-ketanserin). Thus RU 24969 should 
also be considered a 5-HT2 agonist. 
Auerbach et al. (1990) have proposed that RU 24969 functions as a 
presynaptic 5-HT releaser in the hippocampus. However, with regards to 
renin regulation, we have not observed this. Van de Kar et al. (1989) 
found that the 5-HT neurotoxin 5,7-DHT produced a leftward shift in the 
renin dose-response curve to RU 24969, indicating a sensitization of post-
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synaptic 5-HT receptors or receptor mediated events. Those results also 
demonstrate that RU 24969 must be acting in the brain to stimulate renin 
secretion. The present results confirm the previous findings. 
Elevated BP is a potent stimulus to inhibit renin secretion due to a 
reflex stretch receptor mechanism located in the kidney (Tobian et al., 
1959; Hackenthal et al., 1990). RU 24969 elevated BP when administered 
ICV. Thus, it is probable that RU 24969 is stimulating renin secretion 
independently of a cardiovascular mechanism. While iv administration 
caused a decrease in BP (Cherqui et al., 1988), clearly in our hands RU 
24969, administered centrally, caused an elevation. This discrepancy 
could be explained by the location or subtype of 5-HT receptors 
stimulating BP. A previous report suggested that 5-HT1 agonists cause 
hypotension when administered onto the intermediate area of the 
ventrolateral surface of the medulla (Gillis et al., 1989), presumably by 
decreasing sympathetic output to the spinal cord (Saxena and Villalon, 
1990). In contrast, 5-HT2 agonists were reported to increase sympathetic 
nerve discharge and blood pressure (McCall and Harris, 1988; McCall et 
al., 1987). Rittenhouse et al. (1991) found that DOI, a potent 5-HT2 
agonist, increased both blood pressure and renin secretion when 
administered rev, in agreement with the current findings. Thus, it is 
possible that ICV injected RU 24969 is increasing BP and renin through 
brain 5-HT2 receptors, but located at a different sites. Regardless, the 
fact that both renin and blood pressure are elevated in the same direction 
suggests that 5-HT receptor mediated mechanisms are being activated which 
are able to overcome any baroreflex stimulation (as evidenced by the lower 
heart rate following ICV RU 24969 injection). If RU 24969 is stimulating 
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both BP and renin through activation of 5-HT2 receptors in the brain, it 
may explain why there was not a reflex response to lower renin secretion. 
Alternatively, RU 24969 could well be producing a pressor response via a 
5-HT independent mechanism. 
P-chloroamphe~amine 
Fluoxetine selectively inhibits presynaptic 5-HT uptake (Fuller et 
al., 1991), and PeA is a presynaptic 5-HT releaser which enters the 
terminal through this uptake site. Previous studies have shown that 
fluoxetine blocks the PeA-induced release of brain 5-HT (Fuller et al., 
1975; Marsden et al., 1979). Our control experiment revealed that 
fluoxetine also prevented PeA-induced renin secretion (fig. 4.4). These 
results demonstrate that the increase in renin secretion due to PeA is 
mediated via 5-HT and not other neurotransmitters. 
Renin secretion was not stimulated by rev administered PeA. Since PeA 
consistently stimulates renin secretion when injected peripherally (ip), 
we performed experiments to investigate whether elevated blood pressure 
could be masking a renin response to PeA. PeA is known to elevate blood 
pressure (Alper et al., 1987; Stein et al., 1987) which, as mentioned 
above, can cause inhibition of renin secretion through activation of the 
renal stretch receptor. Thus, after rev injection of PCA, blood pressure 
and heart rate were measured to determine if a cardiovascular mechanism 
was inhibiting the renin response. Within 2 minutes, PCA caused a robust 
increase in BP if administered rev, but caused no significant alteration 
when injected ia. This suggested to us that the increase in BP resulting 
from central administration of PeA could cause the inhibition of renin 
secretion. Additionally, since heart rate was elevated at 60 minutes 
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post-injection but blood pressure was not, there was an indication that 
the sympathetic nervous system had been activated. 
The a 1 antagonist prazosin is recognized to cause hypotension via 
blockade of arteriolar a 1 receptors (Cavero and Roach, 1980). PCA causes 
an increase in sympathetic outflow (Alper and Ganong, 1984), and a pressor 
response which can be inhibited by prazosin pretreatment (Alper et al., 
1987). Consequently, the pressor effect of PCA is thought to be mediated 
by the sympathetic nervous system. Alper et al. (1990) reported that if 
prazosin preceded a higher dose of iv injected PCA (6.0 mg/kg), then a 
substantial renin response was exposed. Therefore, we postulated that 
prazosin could also antagonize the hypertensive, and thus, the inhibitory 
effects of ICV administered PCA, using a dose 10-fold (500 µg/kg) lower 
than the iv dose used by Alper. The results shown in figure 4.4 support 
this conclusion. By masking the vasoconstrictive and pressor effects with 
the a 1 antagonist prazosin, PCA's central stimulatory effect on renin was 
revealed. 
The studies performed here, while demonstrating that brain 5-HT 
mediates renin secretion from the kidney, do not characterize the 
mechanism of action. Centrally administered 5- HT has been shown to 
elevate BP and increase Na+ excretion (Montes and Johnson, 1990; Stein et 
al., 1987). Pergola and Alper (1991) postulated that the increase in BP 
caused by ICV 5-HT may be due to the release of vasopressin. Centrally 
administered PCA has also been shown to raise BP and stimulate Na+ 
excretion (Stein et al., 1987), although it apparently does not cause 
neurodegeneration (Berger et al., 1990). Ikonomov et al. (1991) suggested 
that peripherally injected PCA produces increased urine excretion prior to 
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the increase in renin secretion. Collectively, these studies suggest that 
PCA's mechanism of action may be complicated by either direct or indirect 
action on the kidney, and that the increase in renin secretion may occur 
secondarily to elevated Na+ excretion. 
In the present investigation, with the exception of the fluoxetine 
control experiment, all of our studies entailed ICV injection of PCA well 
below peripherally effective doses. While this does not eliminate a 
direct action of PCA on the kidney, it argues in favor of a central site 
of action to increase renin release. Previous reports have provided 
evidence in support of a central site of action for PCA (Van de Kar et 
al., 1981; Karteszi et al., 1982; Van de Kar et al., 1982). Furthermore, 
Gotoh et al (1987) found that electrolytic lesions in either the 
paraventricular or ventromedial nucleus of the hypothalamus inhibited the 
renin response to ip injected PCA. 
In conclusion, our results are consistent with the hypothesis that a 
serotonin agonist and releaser stimulate renin secretion by activating 5-
HT receptors in the brain. We are currently investigating which 
hypothalamic nucleus is responsible for the renin response to RU 24969 and 
PCA. 
CHAPTER V 
NEURONS IN THE HYPOTHALAMIC PARAVENTRICULAR NUCLEUS MEDIATE 
THE SEROTONERGIC STIMULATION OF RENIN SECRETION 
INTRODUCTION 
The regulation of renin release has a prominent central component. In 
the brain, different sites have been proposed which could influence renin 
secretion from the kidney. The hypothalamic PVN (Porter, 1988; Richardson 
Morton et al., 1989) and the VMN (Gotoh et al., 1987; 1988) have both been 
implicated. Dorsal raphe neurons innervate the hypothalamic PVN (Swanson 
and Sawchenko, 1983), where serotonin nerve terminals have been located 
(Liposits et al., 1987; Pazos and Palacios, 1985). Functions of the PVN 
include secretion of vasopressin and oxytocin (Swanson and Sawchenko, 
1983), cardiovascular regulation (Ciriello et al., 1984; Zhang and 
Ciriello, 1985; Takeda et al., 1991; Herzig et al., 1991), feeding 
behavior/energy balance (Leibowitz, 1991) and mediation of the renin 
stress response (Richardson Morton et al., 1989). The VMN is an important 
regulator of weight/energy balance (Tokunaga et al. 1986; Parkinson and 
Weingarten, 1990), thermoregulation (Amir, 1990), lordosis (Schulze and 
Gorzalka, 1991) and has been implicated in cardiovascular function 
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(Valladao et al., 1990). The dorsomedial nucleus, located adjacent to the 
paraventricular and ventromedial nuclei, may also subserve feeding and 
growth regulation (Bernardis et al., 1988) as well as mediating cardiac 
stress responses (Anderson and DiMicco, 1990). 
To determine which nucleus is responsible for regulation of renin 
secretion, we destroyed cells in each nucleus with ibotenic acid. We 
utilized ibotenic acid because it destroys cell bodies while leaving 
fibers of passage intact (Markowska et al., 1985). To limit surrounding 
tissue damage, very low concentrations of ibotenic acid were used 
(Fitzsimons and Ciriello, 1986; Richardson Morton et al., 1989). By 
making discrete lesions with a cell selective neurotoxin rather than 
ablating both fibers and cell bodies electrolytically, we aimed to resolve 
which nucleus contained the receptors necessary for this endocrine 
control. 
Peripherally administered serotonin (5-HT) agonists and releasers 
reliably elevate plasma levels of renin (Van de Kar, 1991). As described 
previously, RU 24969 is an indole derivative considered to be a 5-HT1A/5-
HT1B agonist (Glennon, 1987), but also appears to act at 5-HT2 receptors. 
PCA releases both serotonin and catecholamines from nerve terminals 
(Marsden et al., 1979; Sharp et al., 1986). However, evidence suggests 
that both RU 24969 and PCA increase renin secretion through activation of 
central 5-HT receptors (Van de Kar et al., 1981; 1989). The increase in 
renin caused by PCA is mediated by 5-HT released from neurons originating 
in the dorsal raphe and terminating in the hypothalamus (Karteszi et al., 
1982; Van de Kar et al., 1981 & 1982). These studies demonstrate that 5-
HT neurons in the brain can increase renin secretion from the kidney. 
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Therefore, the purpose of these investigations was to determine if 5-
HT receptors on cells in the hypothalamic PVN, or another adjacent site, 
mediate the renin response to RU 24969 and PCA in conscious male rats. 
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METHODS 
Animals 
Male Sprague-Dawley rats (27S-300g) were purchased from Sasco-King 
Animal Laboratories (Oregon, WI). The rats were housed 2 per cage in a 
climate and illumination (12:12 hr light/dark cycle, lights on at 7:00 AM) 
controlled room. Water and food (Wayne Lab Bl ox, Lab Mills Inc. , Chicago, 
IL) were available ad libitum. All experiments were conducted between 
11 : 00 A. M. and 3 : 00 P. M. All protocols were approved by the Loyola 
University Animal Care and Use Committee, and were conducted in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals. 
Surgery 
Ibotenic acid injections into the hypothalamus were performed under 
pentobarbital (SO mg/kg, ip) anesthesia. Animals were pretreated with 
ampicillin (SO mg/kg, sc) to prevent infection and atropine methyl bromide 
(0.2 mg/kg, ip) to reduce excessive secretions. The vehicle used for 
ibotenic acid was SO mM sodium phosphate buffer, pH 7.2. 
Ibotenic acid was injected at a concentration of 10 µg/µl, in a volume 
of 0.3 µl, (Fitzsimons and Ciriello, 1986) bilaterally over a 10 minute 
period using a 33 gauge guide cannula mounted on a David Kopf stereotaxic 
apparatus. Lesions were made in three separate hypothalamic sites: 1.) 
the PVN, using the coordinates 0.6 mm lateral from lambda, 8.8 mm ventral 
from the skull surface, S. 7 mm rostral to lambda; 2 . ) the DMN, with 
coordinates 0. 8 mm lateral from lambda, 9. 2 mm ventral from the skull 
surface, S.2 mm rostral to lambda; and 3.) the VMN, with coordinates 0.6 
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mm lateral from lambda, 10.2 mm ventral from the skull surface, 4.8 mm 
rostral to lambda (Paxinos and 'Watson, 1986). Rats were allowed two weeks 
recovery after the surgery. 
Protocol 
Following two weeks recovery from surgery, conscious rats were 
administered either RU 24969 (5.0 mg/kg, ip) 30 minutes prior to 
decapitation or PCA (8.0 mg/kg, ip) 60 minutes prior to decapitation. 
Control rats received saline injections. These time points were 
established with previous time-course studies (Van de Kar et al., 1981; 
1989). Trunk blood was collected for radioimmunoassay of renin, and 
brains saved in buffered formalin for histological verification of 
lesions. 
Histology 
Coronal sections (40 µm) were cut on a vibratome, stained with cresyl 
violet and mounted on acid cleaned glass slides. All slides were 
inspected by two investigators who were kept unaware of the hormone data. 
Only animals with histologically confirmed bilateral lesions were used in 
the data analysis. 
Drugs 
PCA and ibotenic acid were purchased from Sigma Chemical Co. (St. 
Louis, MO). RU 24969 was donated by Roussel Uclaf (Romainville, France). 
Both PCA and RU 24969 were dissolved in 0.9% saline. 
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Radioimmunoassays 
Plasma renin activity. Plasma renin activity (PRA) was measured by 
RIA for generated ANG I, as previously described (Richardson Morton et 
al., 1989). Briefly, 1.0 ml plasma samples were incubated for 3 hours at 
37°C to generate ANG I. The antiserum against ANG I was used at a dilution 
of 1:16,000 with total binding of 30%. The sensitivity limit of the RIA 
is 10 pg ANG I per tube. Intra-assay variability was 4.4%, with inter-
assay variability 12. 6% (Richardson Morton et al., 1989). PRA is a 
reflection of the activity of the native enzyme renin in a given plasma 
sample to generate ANG I from endogenous substrate (angiotensinogen). It 
is therefore substrate dependent. 
Plasma renin concentration. Plasma renin concentration (PRC) was 
determined by addition of exogenous renin substrate (0.1 ml of plasma from 
nephrectomized, dexamethasone injected rats) to 50 µl plasma samples and 
incubating at 37°C for 1 hour. The RIA of ANG I was the same as described 
above for plasma renin activity. PRC represents the maximal response 
possible since a saturating concentration of renin substrate is added to 
each plasma sample, and thus is substrate independent. 
We run both PRA and PRC assays to distinguish substrate dependent from 
substrate independent ANG I production, and also to confirm and strengthen 
our renin results. 
Statistics 
The number of rats per group is described in each figure legend. RIA 
data were analyzed using RIA AID software (Robert Maciel Associates, 
Arlington, MA) . Statistical analysis of the data was performed using 
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computer software (STATPAC, NWA, Portland, OR) by 2-way analysis of 
variance (ANOVA). The group means were compared by Newman Keuls' multiple 
range test (Steel and Torrie, 1960). 
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RESULTS 
These experiments were designed to establish which hypothalamic 
nucleus mediates the RU 24969 and PCA-induced stimulation of renin 
secretion. Discrete lesions were made in the PVN with ibotenic acid, a 
cell selective neurotoxin (Markowska et al., 1985). Figure 5.lA-D shows 
the extent of the PVN lesion. A brain section from a vehicle treated rat 
is shown in panel A; note the termination of the cannula tracts at the 
dorsal border of the PVN. Panel B shows the extent of an ibotenic acid 
lesion confined entirely within the PVN; note the very limited amount of 
damage to surrounding tissue. In panel C compare the large magnocellular 
neurons of a vehicle treated rat, to an ibotenic acid lesion in panel D 
where there is nearly a complete absence of cell bodies, but again no 
damage to the remaining tissue. 
Figure 5.2 shows that RU 24969 caused a significant increase of both 
PRA (Fc 1 , 34 ,=44.91, P<0.0001) and PRC (Fc 1 , 33 ,=72.6, P<0.0001). Ibotenic acid 
also had a main effect, causing a reduction in PRA (Fc 1 , 34 ,=4.47, P<0.05) 
and PRC (F0 , 33 ,=4.49, P<0.05). Post-hoc analysis revealed that the renin 
response to RU 24969 was significantly impaired (PRA 46% and PRC 37%) in 
rats with histologically verified PVN lesions compared to vehicle treated, 
RU 24969-injected controls (Newman Keuls' test P<0.05). 
Figure 5.3 shows that PCA also produced a significant increase in PRA 
(F0 , 35 ,=4.87, P<0.05) and PRC (Fc 1, 34 ,=5.42, P<0.05). Ibotenic acid again 
caused a reduction in PRA (Fc 1 , 35 ,-ll.88, P<0.005) but not PRC. In rats 
with histologically verified PVN lesions, ibotenic acid caused a complete 
blockade of the PRA response to PCA (interaction: Fc 1 , 35 ,-ll.88, P<0.005). 
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Post-hoc analysis showed that the PRA and PRC responses to PCA were both 
significantly reduced (PRA >100% and PRC 77%) in animals with PVN lesions, 
compared to vehicle treated controls (Newman Keuls' test P<O. 01 and 
P<0.05, respectively). 
The success rate of ibotenic acid lesions in the PVN varied with each 
group. In the RU 24969 experiment, 13 of 19 RU 24969 treated, and 6 of 14 
saline treated rats had confirmed ibotenic acid lesions in the PVN. In 
the PCA experiment, just 6 of 22 PCA treated, and 8 of 22 saline treated 
rats had confirmed ibotenic acid lesions in the PVN. The primary reason 
for the low rate of confirmed lesions was that we used such small volumes 
in attempting to limit damage within the PVN boundaries, that only a 
precise hit resulted in a complete lesion. Only renin data from those 
rats with confirmed lesions in the PVN are shown in figures 5.2 and 5.3. 
The remaining data from rats with incomplete PVN lesions are summarized in 
Table I. These were considered to have only partial or unilateral damage 
in the PVN. There was no significant inhibition of the renin response to 
RU 24969 or PCA if PVN lesions were incomplete (Table I). 
Figure 5.4 shows coronal sections through the dorsomedial and 
ventromedial hypothalamus. A brain from a vehicle treated rat is shown in 
Panel A. An ibotenic acid lesion in the DMN of the hypothalamus is shown 
in figure 5.4B, with a lesion in the VMN shown in figure 5.4C. Note that 
cell damage is confined to each specific nucleus, while the surrounding 
tissue remains intact. 
As shown in figure 5.5, PCA caused a significant elevation in PRA 
(Fc 1 , 31 >=9.05, P<0.005) and PRC (Fc 1 , 30 >=10.41, P<0.005) in both vehicle 
treated rats and rats with histologically confirmed DMN lesions. There 
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was no difference between either group of animals that received PCA 
injections. Thus, lesions in this nucleus did not change the PCA-induced 
stimulation of renin secretion. There was actually a potentiation of the 
PRC response to PCA in rats with ibotenic acid lesions in this nucleus 
(Fc1,3o>-5.05, P<0.05). 
Finally, as with the DMN lesions, the PCA-induced stimulation of renin 
secretion remained unaltered in rats with VMN lesions. Ibotenic acid had 
no main effect, and there was no significant interaction between ibotenic 
acid and PCA. As shown in figure 5.6, PCA caused a significant elevation 
in PRA and PRC in both vehicle treated rats, and rats with histologically 
confirmed VMN lesions (PRA: Fc 1,34 ,-20. 30, P<O. 0001; PRC: F0 , 34 ,-14. 64, 
P<0.0005). Thus, there was no difference between either group of animals 
that received PCA injections. 
The success rate for DMN and VMN ibotenic acid lesions was somewhat 
better than for the PVN. In the DMN experiment, 10 of 20 PCA treated and 
9 of 16 saline treated rats had confirmed ibotenic acid lesions in the 
DMN. In the VMN experiment, 12 of 18 PCA injected rats and 10 of 16 
saline injected rats had confirmed lesions in the VMN. The PRA and PRC 
data resulting from incomplete ibotenic acid lesions in the VMN or DMN 
were not statistically different from histologically confirmed VMN or DMN 
lesions. Since the two sets of data are virtually identical to each 
other, the PRA and PRC data from incomplete lesions in the DMN or VMN are 
not shown. 
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Figure 5.1. Histological verification of ibotenic acid lesions in 
the hypothalamic paraventricular nucleus. 40 µm coronal sections were 
stained with cresyl violet. 
Panel A: PVN of the hypothalamus, vehicle treated. Cannula tips are 
located on dorsal border of PVN (straight arr ow). 
Panel B: Bilateral ibotenic lesion in PVN. Cannula t ips are within PVN 
boundaries (arrow). 3V, third ventricle. 
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Figure 5.1. Histological verification of ibo teni c acid lesions in 
the hypothalamic paraventr i cular nucleus . 40 µm corona l sections were 
stained with cresyl violet . 
Panel C: Magnocellular neurons of PVN, vehi cle t r eated. 
Panel D: Ibotenic acid lesion in PVN: note absence of neurons . 
97 
CJ saline, ip 
~ RU 24969 (5 mg/kg, ip) 
50 
** ~ 
> 40 I- ~ (...) .c # < ~ z e JO ** z ......... 
w .... 
0::: (.:> 20 z 
< < Cl 
:::!: c 
en -~ 10 
a_ 
0 
VEHICLE IBOTENIC ACID: PVN 
D saline, ip 
z 60 
0 
' 
** 
~ RU 24969 (5 mg/kg ip) 
i 50 
I- ~ z 
w .c 40 u ~ 
# 
** 
z E 
0 ......... 
u .... 30 . 
z (.:> 
z ~ 
w Cl 20 ~ c 
-
. 
< -
:::::E 10 5 
a. 0 
VEHICLE IBOTENIC ACID: PVN 
Figure 5. 2. Ibotenic acid lesions in the PVN inhibit the renin 
response to RU 24969 (ip). Data represent mean± S.E.M. of 8 rats per 
vehicle/saline and vehicle/RU groups, 6 rats in IBO/saline group, and 13 
rats in IBO/RU group. ** Significant difference from corresponding saline 
(0 dose of RU) group, P<O. 01. # Significant difference from corresponding 
vehicle (non-lesion) group, P<0.05 (2-way ANOVA and Newman Keuls' test). 
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Figure 5. 3. Ibotenic acid lesions in the PVN block the renin 
response to PCA (ip). Data represent mean± S.E.M. of 13 rats per 
vehicle/saline group, 11 rats per vehicle/PCA group, 8 rats per IBO/saline 
group, and 6 rats per IBO/PCA group. * or ** Significant difference from 
corresponding saline (0 dose of PCA) group, P<0.05 or P<0.01, 
respectively. # or ## Significant difference from corresponding vehicle 
(non-lesion), PCA injected group, P<0.05 or P<0.01, respectively (2-way 
ANOVA and Newman Keuls' test). 
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Figure 5.4. Histological verification of ibotenic acid lesions in 
the hypothalamic DMN and VMN. 40 µm coronal sections were stained with 
cresyl violet. 
Panel A: DMN and VMN of the hypothalamus, vehicle treated. 3V, third 
ventricle. 
Panel B: Bilateral ibotenic acid lesion in DMN. Cannula tips are within 
DMN boundaries (arrow) . 
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Figure 5.4. Histological verification of iboteni c acid lesions in 
the hypothalamic DMN and VMN. 40 µm coronal sections were stained with 
cresyl violet. 
Panel C: Bilateral ibotenic acid lesion in VMN. Cannula tips are within 
VMN boundaries (arrow). 
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Figure 5.5. Ibotenic acid lesions in the hypothalamic DMN have no 
effect on the renin response to PCA (ip). Data represent mean± S.E.M. of 
8 rats per vehicle/saline group, 7 rats per vehicle/PCA group, 9 rats per 
IBO/saline group, and 10 rats per IBO/PCA group. * or ** Significant 
difference from corresponding saline (0 dose of PCA) group, P<O. 05 or 
P<0.01, respectively (2-way ANOVA and Newman Keuls' test). 
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Figure 5.6. Ibotenic acid lesions in the hypothalamic VMN have no 
effect on the renin response to PCA (ip). Data represent mean± S.E.M. of 
8 rats per vehicle/saline group, 8 rats per vehicle/PCA group, 10 rats per 
IBO/saline group, and 12 rats per IBO/PCA group. * or ** Significant 
difference from corresponding saline group, P<0.05 or P<0.01, respectively 
(2-way ANOVA and Newman Keuls' test). 
TABLE I 
PRA and PRC responses in rats with incomplete (partial or unilateral) 
lesions in the paraventricular nucleus. 
PRA PRC 
ng ANG I/ml/3 hr ng ANG I/ml/hr 
Vehicle/saline 5.1 ± 0.8 (12) 13.5 ± 2.3 (12) 
Ibotenic/saline 4.9 ± 0.6 (14) 14.3 ± 2.5 (14) 
Vehicle/PCA 11.4 ± 2.1 (11)* 28.3 ± 5.1 (11)* 
Ibotenic/PCA 6.8 ± 1. 7 (16) 23.4 ± 3.3 (16) 
Vehicle/saline 6.0 ± 1. 2 (8) 15.7 ± 1. 2 (8) 
Ibotenic/saline 7.7 ± 1. 7 (8) 15.6 ± 1. 7 (8) 
Vehicle/RU 24969 41. 9 ± 7.2 (7) ** 48.6 ± 4.4 (7)** 
Ibotenic/RU 24969 35.6 ± 4.3 (6) ** 47.5 ± 6.9 (6)** 
Data represent mean± S.E.M. * or ** P<0.05 and P<0.01 respectively, 
from Vehicle/saline group (two-way ANOVA, Newman Keuls' multiple 
range test). Figure in parentheses are numbers of animals. 
Ibotenic: ibotenic acid lesions. 
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DISCUSSION 
The results from these studies demonstrate that cell bodies in the PVN 
are necessary to mediate the renin response to the 5-HT agonist RU 24969 
and the 5-HT releaser PCA. In contrast to either DMN or VMN lesions, PVN 
lesions were clearly proficient at inhibiting the renin response to either 
drug. 
We utilized two forms of selectivity in our approach . First, we 
strived to establish discrete lesions within each specific hypothalamic 
nucleus, the paraventricular, dorsomedial or ventromedial, while limiting 
surrounding tissue damage. There are currently no selective 5-HT post-
synaptic receptor toxins. Therefore, we elected to eliminate cell bodies 
thought to contain 5-HT receptors, and maintain our second form of 
selectivity through the use of a post-synaptic 5-HT agonist and a pre-
synaptic 5-HT releaser. If the renin response to these drugs were 
diminished, it would indicate that the neurons responsible (and presumably 
containing the responsible 5-HT receptor subtypes), had been eliminated. 
We only observed this pattern with lesions in the PVN, which argues in 
favor of this nucleus mediating serotonergic control of renin release. 
Consistent with our data, Appel et al. (1990) established that 5-HT2 
binding sites exist in the PVN, and activation of 5-HT2 receptors is known 
to stimulate renin secretion (Van de Kar, 1991). 
It is clear from both the PRA and PRC data that the renin response to 
PCA and RU 24969 was not entirely abolished by PVN lesions. Since our 
lesions were small and confined entirely within the PVN, enough neurons 
could have remained to mediate a partial renin response. This would 
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explain why the renin response to both PCA and RU 24969 was not reduced 
further. These results also suggest a lack of nonspecific tissue damage, 
since larger electrolytic lesions have been shown to more completely 
eliminate the renin response to PCA (Gotoh et al., 1987). These PCA data 
also confirm the predominant central effect of PCA to increase renin 
secretion. It is unclear why the effect of PCA on renin secretion was 
abolished by PVN lesions, whereas the RU 24969 effect was only attenuated. 
The reasons for choosing RU 24969 and PCA as pharmacological tools are 
as follows. Binding studies have characterized RU 24969 as a 5-HT1.Af5-HT1s 
agonist with 100 fold lower affinity for 5-HT1c or 5-HT2 receptors 
(Glennon, 1987; Hoyer and Schoeffter, 1991). However, it has been 
demonstrated that RU 24969 increases renin via post-synaptic 5-HT2 
receptors located in the brain (Van de Kar et al., 1989). The present 
studies confirm the location of the 5-HT receptors in the brain. PCA has 
been characterized as a releaser of 5-HT and catecholamines (Sanders-Bush 
and Steranka, 1978). Evidence that PCA is increasing renin via release of 
5-HT was provided in studies utilizing the 5-HT synthesis inhibitor PCPA, 
which inhibited PCA's stimulation of renin release (Van de Kar et al., 
1981). 
Previous investigations have sought to clarify serotonin's role in 
the brain to regulate renin secretion from the kidney. Dorsal raphe 
lesions with the 5-HT neurotoxin 5,7-DHT, attenuated the renin response to 
PCA (Van de Kar et al., 1982). Efferent connections have been shown to 
exist between the dorsal raphe and the PVN (Swanson and Sawchenko, 1983). 
Karteszi et al. (1982) found that a knife cut severing the midbrain from 
the hypothalamus inhibited the PCA-induced increase in PRA. Furthermore, 
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a large lesion in the mediobasal hypothalamus (the area containing the 
PVN, DMN and VMN) also inhibited the effect of PCA on PRA (Karteszi et 
al., 1982). Thus, the circuitry influencing renin regulation involves 
serotonergic neurons in the dorsal raphe, which terminate in the 
hypothalamus. 
In studies comparable to the present one, Gotoh et al. (1987; 1988) 
made sizable electrolytic lesions in the PVN, DMN, VMN and dorsal raphe 
nucleus. They tested several paradigms which increase renin secretion: 
PCA, immobilization stress, head-up tilt, and a low Na+ diet. The only 
paradigm that PVN and dorsal raphe lesions inhibited was PCA. This 
suggests a serotonergic connection between the dorsal raphe and the PVN, 
as well as differential processing depending on the renin releasing 
stimulus. However, VMN lesions inhibited renin secretion in all of their 
paradigms. Thus, since there was no differential response following VMN 
lesions, it suggests that nonspecific damage may have resulted from 
destroying both neurons and all surrounding fibers of passage. In 
addition, if the VMN were an important regulatory site, then dorsal raphe 
lesions should have inhibited the renin response to the other paradigms, 
which did not occur. We were unable to replicate inhibition of PCA-
stimulated renin secretion with our cell selective VMN lesions. 
In the present study, ibotenic acid lesions in the PVN significantly 
impaired the renin response to RU 24969 and PCA. In contrast, neither DMN 
nor VMN lesions reduced this serotonergic mediated response. Thus, our 
results strengthen the hypothesis that neurons in the PVN, rather than the 
DMN or VMN, mediate the RU 24969 and PCA- induced increase in renin 
secretion. Furthermore the results suggest that fibers of passage, or 
107 
connections running between the PVN and the VMN, rather than cells in the 
VMN, are mediating the PCA-induced renin elevations seen by Gotoh et al. 
(1987). Since our lesions were confined to each designated nucleus, the 
evidence presented here supports the PVN as the serotonergic integrator 
for renin secretion. 
It is quite likely that different renin-releasing stimuli (such as 
immobilization stress, head-up tilt or low Na+ diet) would converge on the 
hypothalamus, to form a common final output pathway to the kidney. The 
stimuli would not necessarily have to be mediated by 5-HT, but only 
synapse in the hypothalamus. The VMN may lie along the output pathway, 
which would explain why nonspecific electrolytic lesions blocked the renin 
response to so many different stimuli. Evidence for this anatomical 
arrangement suggests that connections from forebrain structures such as 
the subfornical organ may traverse through the VMN to the brain stem where 
they influence cardiovascular function and body fluid homeostasis (Hartle 
and Brody, 1984; Knuepfer et al., 1984; Ciriello and Gutman, 1991). 
Two possible functions are proposed for PVN regulation of renin 
release. We have shown repeatedly that a variety of stressors increase 
renin (Van de Kar et al., 1991). For example, the renin response to 
conditioned fear stress is mediated by PVN cells (Richardson Morton et 
al., 1989). In addition, since the paraventricular nucleus clearly plays 
a vital role in integrating body fluid homeostasis, it would not be 
surprising if renin release from the kidney were also regulated from this 
site. The mechanism may be either hormonal (Van de Kar et al., 1987) or 
involve the sympathetic nervous system (Ciriello and Calaresu, 1980; Alper 
and Ganong, 1984; Hosoya et al., 1991). 
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In summary, these studies provide evidence that cell bodies in the PVN 
mediate the renin response to a serotonin agonist and releaser. It 
appears that cells within the VMN or DMN are not required for this action. 
These results also confirm previous reports suggesting 5-HT regulates 
renin secretion through central 5-HT receptors. 
CHAPTER VI 
DISCUSSION 
Summary. The hypothesis to be tested by this dissertation was that 
serotonergic receptors on hypothalamic paraventricular neurons mediate 
renin secretion from the kidney. To answer this, two questions were 
asked. First, are the 5-HT receptors located in the brain, and two, if 
they are, is the site in the PVN or some other site. The present data 
provide answers to these two questions, given the limitations of the 
pharmacological tools available. The 5-HT agonists DOI and RU 24969, and 
the 5-HT releaser PCA were all found to stimulate renin secretion by 
activating 5-HT receptors in the brain. DOI had an additional mechanism 
of action peripherally, and was therefore not used in the subsequent 
studies. Upon creating chemical, cell-selective lesions in three 
different hypothalamic nuclei, only those lesions in the paraventricular 
nucleus inhibited the renin response to RU 24969 and PCA. These data 
suggest that cell bodies in the PVN are necessary to mediate the renin 
response to a 5-HT agonist and 5-HT releaser. The remainder of this 
discussion will summarize the data, analyze issues that are unclear, and 
frame the results into a more global picture. An attempt will be made not 
to rediscuss issues already explored in each of the three papers presented 
as chapters. 
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Pharmacology of drugs used for these studies. The three drugs used 
to study the serotonergic stimulation of renin secretion were DOI, RU 
24969 and PCA. They were chosen because each have been shown to increase 
renin secretion dose-dependently when administered peripherally (Van de 
Kar et al., 1981; 1989). They represented different drug classes with 
different mechanisms of action. 
RU 24969 is an indole compound resembling 5-HT, initially classified 
by binding studies as a 5-HT1A/5-HT1B agonist (Glennon, 1987). However, 
other data suggest that Ru 24969 can bind with higher affinity to the 5-HT2 
"high-affinity" site (defined by 3H-DOB binding) than to the 5-HT2 "low-
affinity" site (defined by 3H-ketanserin binding, Lyon et al., 1987), and 
may now be considered to have 5-HT2 agonist properties. Clearly, it is 
capable of stimulating renin secretion through a 5-HT2 mediated mechanism 
(Van de Kar et al., 1989). 
DOI is an aminopropane with 5-HT agonist characteristics and an 
extremely high affinity for 5-HT1c/5-HT2 binding sites (Shannon et al., 
1984). Previous evidence using high affinity 5-HT2 antagonists suggested 
that renin was stimulated by 5-HT2 receptor activation (Lorens and Van de 
Kar, 1987). Until the development of DOI and agents similar to it, no 
high affinity agonists existed which could be tested for 5-HT2 mediated 
effects. DOI was chosen for these reasons. 
PCA is an amphetamine derivative, shown to release 5-HT (Sanders-Bush 
and Steranka, 1978; Marsden et al., 1979). PCA has been used repeatedly 
to stimulate renin secretion. As a 5-HT releaser, it was originally used 
to provide evidence that brain serotonergic systems could be involved in 
renin regulation (Van de Kar et al., 1981; Karteszi et al., 1982). A 
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possible drawback to the use of PCA was the issue raised by Ikonomov et 
al. (1991), who maintain that peripherally administered PCA damages the 
kidney, and any subsequent renin data are questionable. Three of my 
experiments (ICV dose response, cardiovascular parameters, and prazosin) 
used doses of PCA below those peripherally effective, and were injected 
into the brain !CV. The possibility of kidney damage cannot be ruled out, 
but is unlikely, in these experiments. The other PCA experiments 
(fluoxetine and the ibotenic acid studies), did involve peripheral 
injections. Of more importance is the issue that renin secretion may be 
occurring secondarily to elevated NA+ excretion (Stein et al., 1987). 
Further tests would have to be carried out to determine if centrally 
administered PCA was increasing renin through a direct or indirect 
mechanism. 
Chapter III: DOI experiments. The purpose of the experiments in this 
chapter was to determine the identity and location of the 5-HT receptor 
subtype(s) mediating the renin and blood pressure responses to DOI. DOI 
injected ip into conscious male rats elevated plasma renin activity in a 
dose-dependent manner. The 5-HT1c/5-HT2 antagonist ritanserin completely 
blocked the DOI-induced increase in plasma renin activity and 
concentration. In order to distinguish the 5-HT2 from the 5-HT1c mediated 
effect of DOI, spiperone was administered prior to DOI. Low doses of 
spiperone (sc) significantly reduced the renin response to DOI. Since 
spiperone has a higher affinity for 5-HT2 than 5-HT1c receptors, these data 
suggest that DOI stimulates renin secretion through 5-HT2 receptors. To 
separate central from peripheral 5-HT receptors, DOI was injected in rats 
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pretreated with saline or xylamidine, a 5-HT2 antagonist which does not 
cross the blood brain barrier. Xylamidine produced a shift to the right 
and suppression of the maximal effect of DOI on plasma renin activity and 
concentration, suggesting a role for peripheral 5-HT2 receptors in the 
effect of DOI. On the other hand, ICV administration of DOI, using doses 
lower than the peripherally effective doses, caused a significant 
elevation of plasma renin activity. These experiments suggest that DOI's 
elevation of plasma renin activity has both peripheral and central sites 
of action. To determine if BP changes were responsible for DOI's effects, 
BP was measured after injection of DOI (IeV). A dose-dependent rise in 
BP occurred within 10 minutes post-injection, in contrast to ia injection 
of DOI which produced a slower and lower BP rise. Heart rate (HR) was 
significantly reduced after rev but not after ia injection of DOI. The 
increase in plasma renin concentration after rev injection of DOI was 
significantly higher than the corresponding value after ia injection of 
the same dose of DOI. To summarize, these data suggest that DOI increases 
renin secretion and elevates BP by activating both peripheral and brain 5-
HT receptors. 
Several issues raised by the data need to be addressed. The data from 
this study show that the renin response to DOI was clearly blocked by 
ritanserin (ip). However, the renin response was only attenuated, but not 
abolished by spiperone. To conclude that renin is regulated by 5-HT2 
receptors, it would have been more convincing to see a separation of the 
renin response between the two doses of spiperone. That is, if spiperone 
were only antagonizing 5-HT2 receptors at the low dose, but antagonized 
both 5-HT2 and 5-HT1c receptors at the high dose, we might expect to see 
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an even greater inhibition of the DOI effect on renin release at the 
higher dose. Alternatively, a separation could be interpreted as meaning 
that more 5-HT2 receptors were antagonized, especially if the hypothesis 
is that renin is regulated by only 5-HT2 and not 5-HT1c receptors. It 
could be that the higher dose of spiperone used, which was only 10 fold 
higher than the low dose, simply was not great enough to discern a 
receptor differentiation since the two receptors are so similar. A final 
interpretation could be that both 5-HT2 and 5-HT1c receptors contribute to 
renin regulation. Thus, at each dose, spiperone would antagonize a 
portion of the renin response mediated by 5-HT2 receptors, and a portion 
mediated by 5-HT1c receptors, with no differentiation between spiperone 
doses distinguishable. In any event, the fact that the low dose of 
spiperone inhibited the renin response to DOI, suggests that 5-HT2 
receptors are likely involved in renin regulation. 
Another question is why did the same doses of ritanserin completely 
eliminate the renin response to DOI, compared to spiperone and xylamidine. 
The simplest explanation is that ritanserin was antagonizing non-
competitively, while spiperone and xylamidine were antagonizing 
competitively. Ritanserin has been shown to noncompetitively inhibit 
[ 3H]ketanserin binding (Leysen et al., 1985). Considering how low a dose 
of ritanserin was used, the renin response blockade was impressive. This 
suggests that, in contrast to either spiperone or xylamidine, ritanserin 
could be blocking both peripheral and central 5-HT2 receptors, or some 
other receptors involved in renin regulation. Ri tanserin appears to 
remove receptors from availability, making any dose of DOI ineffective. In 
support of this, Bond et al. (1989) found that 5-HT2 antagonists were 
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producing renal vasoconstriction by a proposed "pseudoirreversible 
inhibition" of 5-HT receptors, resulting in the appearance of 
unsurmountable (or noncompetitive) antagonism. Although the maximal renin 
response to DOI was blunted by both spiperone and xylamidine, the case 
that they are also inhibiting in a noncompetitive manner is not as strong 
as with ritanserin, but should still be considered. 
Since the renin and blood pressure responses were not attenuated by a 
centrally administered 5-HT2 antagonist, a strong case cannot be made that 
5-HT2 receptors in the brain mediate these responses to DOI. The 
explanation for why !CV ritanserin did not inhibit the renin response to 
DOI is puzzling. The dose used (2.0 µg/kg, !CV) should have been high 
enough considering that 10 µg/kg (sc) completely abolished the response 
peripherally. One possibility is that at the doses used, DOI was capable 
of stimulating both central and peripheral receptors, while ritanserin 
could only antagonize the central sites. Another explanation is that 
ritanserin could be metabolized peripherally to a compound that interacts 
non-competitively with 5-HT receptors. The !CV renin dose-response to DOI 
does suggest, however, that central receptors were activated. And 
clearly, the BP response to !CV injected DOI is faster and more robust 
than peripherally injected DOI, again suggesting that both central and 
peripheral sites are activated by DOI. A recent report agrees that DOI 
stimulates BP through separate mechanisms centrally compared to 
peripherally (Dedeoglu and Fisher, 1991). This is not surprising since 5-
HT2 receptors are located on a number of important cardiovascular sites, 
including vascular smooth muscle and platelets (Saxena and Villalon, 
1990). However, the argument could be made that since DOI is such a 
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selective 5-HT1c/5-HT2 agonist (Shannon et al., 1984), that presumably any 
response that is occurring in the brain must be mediated by those receptor 
subtypes. Other evidence agrees with this conclusion. 5-HT2 receptors 
have been localized in the PVN (Appel et al., 1990). DOI applied to the 
ventrolateral medulla increases blood pressure and sympathetic output 
(McCall and Harris, 1988; Mandal et al., 1990a). DOI-induced renin 
secretion could be inhibited by the peripherally and centrally acting 5-
HT2/5-HT1c antagonist LY53857 (Alper, 1990a). 
A final point, is that the peripheral (ip) dose of DOI which 
significantly and maximally increased renin secretion was 2.0 mg/kg (fig. 
3.1). In contrast, the ICV dose needed to significantly increase renin 
secretion was 0. 2 mg/kg (fig. 3. 5) , which is 10 times lower. This 
suggests that 0.2 mg/kg injected into the brain would be too low a dose to 
stimulate renin secretion even if it diffused out of the brain and reached 
peripheral targets. Taken together, the results presented here agree with 
previous reports that DOI can stimulate renin secretion through central 5-
HT2 receptors, but do not exclude the contribution of peripheral receptors. 
Chapter IV: !CV experiments with RU 24969 and PCA. The next set of 
experiments examined whether RU 24969 or PCA have a central site of action 
to increase renin release. The mechanism of action of fluoxetine is to 
block the high affinity 5-HT uptake transporter (Fuller et al., 1991). 
PCA enters 5-HT nerve terminals by this same mechanism. Thus, since 
fluoxetine blocked the renin response to PCA, these results confirm that 
the renin response to PCA is mediated by nerve terminals containing 5-HT, 
rather than some other neurotransmitter. ICV injection of a low dose of 
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the 5-HT1c/5-HT2 antagonist LY53857 inhibited the renin response to 
peripherally injected RU 24969. These data suggest that ip injected RU 
24969 activates brain 5-HT2 receptors to increase renin secretion. 
Subsequently, RU 24969 or PeA were injected rev at doses below those 
peripherally effective. While RU 24969 dose-dependently increased plasma 
levels of renin, PeA did not. To determine if a cardiovascular mechanism 
was preventing PeA from stimulating renin, BP and HR were recorded. RU 
24969 (IeV) induced a mild but significant BP elevation of 18 mm Hg, 5 
minutes after injection. PeA (IeV) produced a larger rise of 44 mm Hg at 
2 and 5 minutes after injection. Neither drug administered peripherally 
(ia) had a significant effect on BP. These data suggest that the large 
elevation in BP, resulting from rev administration of PeA, could be 
causing the inhibition of renin secretion. Indeed, PeA injected IeV 
significantly increased renin secretion if preceded by the a 1 antagonist 
prazosin. Thus, by inhibiting the cardiovascular effects with prazosin, 
PeA's central stimulation of renin secretion was exposed. In conclusion, 
these data suggest that both RU 24969 and PeA increase renin secretion 
through central 5-HT receptors, rather than through a cardiovascular 
mechanism. 
PeA stimulation of renin occurs after ip administration (Van de Kar et 
al., 1981). When injected iv (Alper et al., 1990) or IeV as in these 
experiments, PeA does not increase renin secretion unless preceded by 
prazosin. Prazosin is an a 1 antagonist known to cause vasodilation, 
hypotension and inhibition of sympathetic nerve activity (eavero and 
Roach, 1980). rev administration of PeA produced a rapid and sizable 
elevation in BP. An increase in renal arterial pressure activates renal 
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stretch receptors, which inhibit renin secretion (Hackenthal et al. , 
1990). While blood pressure was not measured in these experiments after 
prazosin treatment, a previous study showed that prazosin does inhibit the 
blood pressure response to PCA (Alper et al., 1987). Additionally, 
paradigms designed to inhibit S-HT (S,7-DHT; fluoxetine), did not reduce 
the BP response to PCA (Alper et al., 1987), suggesting PCA's pressor 
response is not mediated by serotonergic systems. These studies, plus the 
combined data from the fluoxetine and prazosin experiments, demonstrate 
that PCA is stimulating renin secretion via a serotonergic mechanism, 
rather than a cardiovascular mechanism. 
It could be argued that the !CV administered drugs "leaked" from the 
brain to the periphery. While the time course of drug administration does 
allow for this possibility, it is unlikely for one primary reason, which 
is dosage. The 
concentrations. 
doses were all well below peripherally effective 
Consider that LYS38S7 was injected !CV at SO µg/kg 
compared to 1.0 mg/kg used by Van de Kar et al. (1989). Their dose of 
LYS38S7 was 20 times higher than the dose used here and still did not 
completely eliminate the renin response to RU 24969. This suggests that 
the dose of SO µg/kg was low enough to ensure that inhibition of S-HT 
receptors was occurring in the brain and not in the periphery. The 
highest dose of RU 24969 injected ICV was 200 µg/kg, compared to the 
lowest peripherally effective dose of 1.0 mg/kg, which is S-fold higher. 
In addition, it should be noted that the lowest effective dose of RU 24969 
injected rev was 100 µg/kg, 10-fold lower than the peripheral dose of 1.0 
mg/kg. The highest dose of PCA injected !CV was 1.0 mg/kg compared to the 
lowest peripherally effective dose of S.O mg/kg (Van de Kar et al., 1981). 
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However, since this dose (1.0 mg/kg) did not increase renin due to PCA's 
potent pressor effects, the proper comparison is between the 0.5 mg/kg 
dose of PCA injected ICV following prazosin, and the 6.0 mg/kg (iv) dose 
used by Alper et al. (1990) following prazosin. Their dose was over 10-
fold higher than the dose used here. Yet their 10-fold higher dose could 
not produce the same increase in renin as seen after 0.5 mg/kg ICV. Taken 
together, these comparisons do not rule out peripheral effects of these 
drugs once they have been injected into the ventricles. However, these 
doses do suggest that the most likely explanation for a renin response 
following ICV administration RU 24969 and PCA is that it is due to 
activation of brain 5-HT receptors. 
Chapter V: Hypothalamic lesion experiments. The final group of 
experiments were designed to resolve which hypothalamic nucleus is 
necessary for the serotonergic control of renin secretion. Previous 
studies suggest that serotonergic neurons, projecting to the hypothalamus, 
mediate the effect of PCA on renin secretion. Discrete cell-selective 
lesions were made with ibotenic acid in three hypothalamic sites: the 
paraventricular, the dorsomedial or the ventromedial nuclei. The renin 
response to both RU 24969 (ip) and PCA (ip) was significantly reduced in 
rats with histologically verified PVN lesions compared to vehicle treated 
controls. In contrast, the renin response to PCA remained unchanged in 
rats with either DMN or VMN hypothalamic lesions. Thus, these results are 
consistent with the hypothesis that 5-HT receptors located on cell bodies 
in the PVN mediate the renin response to a serotonin agonist and releaser. 
Furthermore, these lesion studies confirm previous studies that suggest 
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that 5-HT neurons regulate renin secretion through central receptors (Van 
de Kar et al., 1981; 1982; 1989; 1990; Karteszi et al., 1982). 
These experiments, combined with previous studies (Van de Kar et al., 
1990; Appel et al., 1990), suggest that the 5-HT receptor subtype in the 
PVN mediating the renin response may be 5-HT2 • RU 24969 is a 5-HTuf5-HT1B 
agonist, but clearly has 5-HT2 agonist properties. However, these data 
cannot be considered conclusive evidence that 5-HT2 receptors in the PVN 
mediate the renin response to 5-HT. A single 10 µg/kg dose of RU 24969 
has been injected directly into the PVN, and caused a significant increase 
in plasma renin concentration (Van de Kar et al., 1990). Even more 
conclusive would be a renin dose-response experiment with a selective 
agonist such as DOI injected directly into the PVN, and inhibited with a 
selective 5-HT2 antagonist. 
The rationale for the choice of ibotenic acid as a method for 
destroying cell bodies and their complement of receptors is as follows. 
Electrolytic lesions have already been successfully used to destroy both 
the PVN and VMN (Gotoh et al., 1987; 1988). The electrolytic technique, 
while certainly complete, has the disadvantage of usually leaving large 
holes in the brain encompassing areas of tissue in excess of the 
designated target site. Two other toxins could have been used, EEDQ or 
5,7-DHT. The irreversible receptor inactivator EEDQ, eliminates all 5-HT 
receptor subtypes (Battaglia, personal communication). This procedure 
would not selectively differentiate 5-HT receptor types. This could be 
overcome by use of selective agonists. However, EEDQ receptor 
inactivation could not easily be verified by histology, and would require 
extensive autoradiographic verification procedures. A second possibility 
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would have been to use the serotonin neurotoxin 5,7-DHT. This toxin is 
taken up presynaptically to destroy 5-HT nerve terminals and cell bodies 
(Van de Kar et al., 1982). Thus, all post- synaptic receptors would 
remain. The only paradigm this lesion would inhibit is one utilizing the 
presynaptic 5-HT releaser PCA. Elimination of nerve terminals may cause 
up-regulation of post-synaptic receptors, and a subsequent shift to the 
left of dose-response curves. Presumably, this is due to the development 
of post-synaptic supersensitivity. This toxin also requires a difficult 
verification procedures such as 5-HT assay of brain tissue "punches" or 
autoradiography of [ 3H]-citalopram binding to 5-HT uptake sites located on 
presynaptic 5-HT terminals. The toxin used in my studies, ibotenic acid, 
has been verified to destroy cell bodies and presumably their receptors 
(Markowska et al., 1985). However, the advantage over electrolytic 
lesions is that fibers of passage are left intact. Receptor selectivity 
is maintained by use of specific direct or indirect agonists, in this 
case, RU 24969 and PCA. Verification of ibotenic acid lesions entails 
simple histology with cresyl violet staining. None of the above mentioned 
procedures is perfect, but they are currently the best available. 
Ibotenic acid lesions were previously made in the PVN, and inhibited the 
renin response to a conditioned fear procedure (Richardson Morton et al., 
1989). In addition, the excitotoxin N-methyl-D-aspartic acid (NMDA) has 
been used to produce lesions in the PVN (Rockhold et al., 1990). NMDA 
also destroys cell bodies and leaves fibers of passage intact. These 
lesions altered blood pressure acutely (1-2 hours), and produced some 
apparent myocardial necrosis, but renin was not measured. 
Receptor selectivity, as just mentioned, was maintained through the 
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use of selective 5-HT agonists. Why not inject 5-HT directly into the 
brain and measure renin secretion? First of all, evidence discussed 
earlier indicates that renin is regulated by 5-HT2 receptors. Secondly, 
5-HT has, by definition, high affinity for 5-HT1 receptors and low affinity 
for 5-HT2 receptors. Although, it has become clear recently, that the 5-
HT2 receptor also exists in a high affinity state (Lyon et al, 1987). 
Thus, dissecting out which receptor was responsible for which response 
would be nearly impossible without highly effective antagonists. The 
simpler approach would be to use selective agonists known to stimulate 
renin secretion, which was the method employed here. Finally, 5-HT would 
be rapidly taken up by the high affinity presynaptic uptake mechanism or 
metabolized by monoamine oxidase. Therefore, quantifying how much 5-HT 
reaches a particular receptor site would be difficult to estimate. 
Comparison of results with the literature. The inspiration for these 
experiments came from two sets of data in the literature. The first being 
from Alper's laboratory, who carried out studies suggesting that 5-HT2 
agonists such as quipazine and DOI were increasing renin secretion by 
decreasing renal blood flow, not by acting in the brain (Zink et al., 
1990; Alper, 1990a). The data presented here support the hypothesis that 
5-HT receptors in the brain can stimulate renin secretion, but do not 
contradict Alper's earlier findings of possible peripheral mechanisms. 
The second source came from Ganong' s group, who performed studies 
suggesting that the VMN, PVN or both might regulate renin secretion from 
the kidney (Gotoh et al., 1987; 1988). Their findings demonstrated that 
electrolytic lesions in the PVN inhibited the renin response to PCA, while 
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electrolytic lesions in the VMN inhibited the renin response to a variety 
of stimuli, including PCA. The results reported here do not support the 
VMN as the likely site for the serotonergic receptors influencing renin 
secretion, but do support the PVN. Since the electrolytic lesions used by 
Gotoh also destroyed fibers of passage, it is probable that the VMN lies 
along a pathway important for fluid homeostasis. Evidence for such a 
pathway exists (Hartle and Brody, 1984; Ciriello and Gutman, 1991). 
Where do these results fit in with overall regulation of kidney 
function? The renin-angiotensin system (RAS) is designed to respond to 
hypotension, blood loss, and Na+ loss. The RAS is also necessary to 
regulate homeostatic fluid and electrolyte balance. If the kidney is the 
ultimate "manager" of the arterial pressure setpoint, as postulated by 
Guyton (1972; 1990), then why would the brain be involved in control of 
renin secretion? There are several credible answers to this question. 
The first explanation is that renin as a neuroendocrine factor, is 
very responsive to stress (Van de Kar et al., 1991). The 5-HT1A anxiolytic 
ipsapirone has attenuated the effects of immobilization and conditioned 
fear on renin secretion (Rittenhouse et al., 1992). Lesions in the PVN 
inhibited the renin response to conditioned fear (Richardson Morton et 
al., 1989). These studies suggest that renin is a "stress hormone" or 
marker, as reactive to stress as ACTH, corticosterone and prolactin (Van 
de Kar et al., 1991). Since the physical stressor of hemorrhage potently 
releases renin, it is not surprising that other physical stressors 
(immobilization) or more "emotional" stressors (conditioned fear) would 
also stimulate renin. In each situation, the organism is preparing to 
deal with a real or perceived environmental insult which could threaten 
123 
fluid balance. This notion is based fundamentally on Cannon's hypothesis 
of stress: that an organism will prepare itself for "fight or flight". 
Mobilization of the renin-angiotensin system as part of the generalized 
alarm response, is an appropriate response in anticipation of possible 
injury or wounds in a fight/flight situation. ANG II has the important 
responsibility of redirecting blood from enteric pools to vital organs 
(brain and heart) in response to serious injury (Keeton and Campbell, 
1980). In addition, it is not surprising that renin secretion would 
increase in response to stress, since the hallmark of the stress-response 
is activation of the sympathetic nervous system, which also stimulates 
renin release through p receptors in, and outside the kidney. Perceived 
stress, as occurs during conditioned fear, would obviously have to be 
mediated through the brain, as no physical element is involved. 
Nonetheless, stress in any form, may be capable of activating the 
generalized stress response, and with it, the renin-angiotensin system. 
Given the previous work by Richardson Morton et al. (1989), and the data 
presented here, the PVN is very likely an integrative center for stress-
induced renin release. 
The second explanation of why the brain would be regulating renin 
secretion is based on known autonomic and endocrine functions of the PVN 
(Swanson and Sawchenko, 1983). The anatomy and connections of the PVN 
certainly suggest an additional integrative role. There are a reported 30 
neuroactive substances within the PVN, a bilateral structure bordering the 
third ventricle, with each side comprising only 0. 3 mm2 of tissue. The PVN 
has been estimated to contain less than 10,000 cells, approximately 1700 
large magnocellular neurons and approximately 7000 smaller parvocellular 
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neurons (Swanson and Sawchenko, 1983). 
The PVN sends efferent projections in several directions, for example 
rostrally, to the subfornical organ, the OVLT, and preoptic area (Larsen 
et al., 1991). Caudally, efferents extend to the spinal cord where direct 
connections are made with preganglionic sympathetic cell groups (Hosoya et 
al., 1991). Ventrally, the PVN sends major projections to the median 
eminence and neurohypophysis along the hypothalamo-pituitary tract 
(Swanson and Sawchenko, 1983). And finally there are dorsomedial 
projections to midline structures such as the thalamus, periaquaductal 
gray and area postrema (Larsen et al., 1991; Shapiro and Miselis, 1985). 
The PVN receives afferent noradrenergic and adrenergic inputs from the 
ventrolateral medulla (A1 and C1 ) the nucleus of the solitary tract (NTS, 
A2 and C2), and the locus coeruleus (Cunningham et al., 1990; Weiss and 
Hatton, 1990a). The dorsal raphe sends limited projections to the PVN 
(Swanson and Sawchenko, 1983). Interconnections exist within the 
hypothalamus from the DMN, VMN, preoptic area, anterior and lateral 
hypothalamus (Swanson and Sawchenko, 1983). The PVN also receives a 
prominent ANG II input pathway from the subfornical organ (Weiss and 
Hatton, 1990b; Lind et al., 1985). Lastly, limbic structures including 
the central nucleus of the amygdala, hippocampal formation, and septal 
region send afferents to the PVN (Swanson and Sawchenko, 1983). These 
anatomical connections, both afferent and efferent, suggest that the PVN 
is in a central position to act as an integrator of cardiovascular and 
visceral information. 
The kidney receives direct CNS input via the sympathetic nerves. It 
could be speculated, that the brain may be vital in establishing the 
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"setpoint" discussed by Guyton (1972, 1990). If this is the case, then 
dysfunction anywhere along the integrative network which includes the PVN, 
could contribute or even be causative for the development of hypertension. 
Electrolytic lesions in the subfornical organ (Hartle and Brody, 1984), 
area postrema (Mangiapane et al., 1989), and PVN (Ciriello et al., 1984; 
Takeda et al., 1991; Herzig et al., 1991) attenuated either development or 
maintenance of hypertension in experimental models of hypertension. Thus, 
dysfunction of central pressor pathways containing the PVN could 
contribute to essential hypertension (Ferrario and Averill, 1991). 
Finally, if the PVN is a central integrator or at least modulator of 
renal function, it is in an ideal position to monitor feedback signals 
from the kidney, presumably via blood borne ANG II. ANG II receptors are 
present in both the subfornical organ and PVN (Lind et al., 1985), and the 
PVN receives and sends projections to all the circumventricular organs 
(Larsen et al., 1991), which lie outside the blood-brain barrier. An 
established mechanism whereby the PVN could have a direct impact on renal 
function, is via the sympathetic nerves (Brody, 1988). Alternatively, the 
PVN may be stimulating renin secretion by a putative renin releasing 
factor (Urban et al., 1985; Van de Kar et al., 1987). 
The dorsal and median raphe nuclei send efferent 5-HT projections to 
most of the structures in the brain. Six major ascending pathways have 
been identified, with substantial overlap between them. The dorsal raphe 
sends projections to the frontal cortex (basal ganglia and amygdala), 
striatum (caudate/putamen), and via the periventricular tract to the 
thalamus and hypothalamus. The median raphe sends projections to frontal 
cortex ( cingulate, hippocampus and septum) , and along with the dorsal 
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raphe, to the mammillary bodies (Azmitia and Segal, 1978; Molliver, 1987). 
5-HT nerve terminals originating from the dorsal raphe have been 
identified in the subfornical organ (Lind, 1986) and the OVLT (Bosler and 
Descarries, 1988). The area postrema also contains 5-HT immunoreactive 
cells and fibers (Newton et al., 1985). Each of these circumventricular 
organs have afferent and efferent connections with the PVN (Larsen et al., 
1991). 
Conclusion. Two conclusions can be made from the results presented in 
this dissertation. First, 5-HT can act both in the brain and periphery to 
stimulate renin secretion. A central response was elicited by the 5-HT 
agonists DOI, RU 24969, and PCA to stimulate renin secretion. Second, 
neurons in the PVN mediate renin secretion to two serotonin agonists, RU 
24969 and PCA. Therefore the receptors are most likely serotonergic. 
The PVN is ideally situated to be a central integrator for 
cardiovascular and fluid homeostasis, which are closely linked functions. 
The PVN receives serotonergic input from the dorsal raphe and ANG II input 
from the subfornical organ, in addition to having efferent projections to 
all of the circumventricular organs. In this capacity it may also act as 
a feedback site for ANG II produced by the kidney, mediated in part by 5-
HT from the dorsal raphe. Thus, by whatever pathway or mechanism the PVN 
receives its information, the net output signal results in altered renin 
secretion from the kidney. Since baseline renin secretion did not change 
following PVN lesions, it is unlikely that the PVN exerts a tonic input to 
the kidney, but rather responds to environmental stimuli to increase renin 
secretion. Some of these environmental stimuli must be mediated by 5-HT, 
127 
since PVN lesions retarded the renin response to 5-HT agonists. Thus, 5-
HT may play an important role in the PVN as a regulator of renin 
secretion. 
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